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ABSTRACT

Off-label prescribing is a common and legal practice in the United States. However, offlabel prescribing occurs oftentimes with inadequate evidence of effectiveness. Such practice,
especially when prescribing for disease conditions different from approved clinical indications
(indication-based off-label prescribing), brings about controversy and raises different issues with
various stakeholders. Although indication-based off-label prescribing offers advantages in terms
of providing innovative therapy, it raises concerns because the safety and efficacy of such use
may not be evaluated adequately. Thus, the objective of the study was to examine whether
pharmacists are willing to influence physicians while evaluating an indication-based off-label
medication order. Based on the extended social power typology originally proposed by French
and Raven (1965), the study examined the role of relative expert power, perceived
appropriateness, and perceived negative relational consequences on pharmacist’s willingness to
influence using rationality tactic.
Pharmacists practicing in hospitals were recruited from the membership rolls of state
affiliates of the American Society of Health-System Pharmacists (ASHP). The state affiliates
were requested to distribute to their members an invitation to participate that contained a link to
the survey instrument. The study employed a 2 X 2 experimental design in which relative expert
power and appropriateness were manipulated using a hypothetical vignette. Respondents who
reported practicing in a hospital were randomly assigned to one of the four experimental groups.
Responses from 267 pharmacists were available for analysis.

After consistency

inspection, 242 pharmacist respondents were included in the analysis to examine the various
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propositions.

Results of the analysis showed that, in general, pharmacists were willing to

influence physicians to ensure rationality of indication-based off-label prescribing. Although
small in magnitude, pharmacists did express concern about negative impact on inter-professional
relationship quality that might arise due to influence attempts. Indeed, the effect of perceived
expert power differential between the physician and pharmacist and the effect of perceived
appropriateness of the off-label medication order on willingness to influence were strongly
(p<0.05) moderated by perceived impact on relationship quality. In addition, the perceived
expert power differential was associated with pharmacists’ willingness to influence.
Pharmacists’ willingness to influence increased as perceived appropriateness decreased.
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CHAPTER 1
INTRODUCTION
Physicians prescribe medications with an expectation that they are safe and effective.
Despite these two basic assumptions, it is understood that a medication may fail to provide the
expected therapeutic effect or have associated with its use, side effects. In other words, an
approved medication, prescribed for a labeled (approved) indication, may have associated with it
any outcome from harmful to safe and from ineffective to effective. In addition to prescribing
practices that are consistent with product labeling, prescribers are granted the right to prescribe
medications outside of approved indications or allowed to choose therapies that have not yet
received approval from the Food and Drug Administration (FDA). Off-label prescribing is an
example of such a privilege. Off-label prescribing can be considered an experimental treatment,
a standard therapy, or state-of-the-art pharmacotherapeutic practice.

Naturally, off-label

prescribing has drawn a lot of attention in the media and among policy makers and has been
subject of academic inquiry for years.

Off-label Prescribing
Off-label prescribing is the act of prescribing of a medication in a way that is not
authorized or approved by a drug approval authority in a country (e.g., the FDA in the United
States) (Cuzzolin, Zaccaron, and Fanos, 2003). There are different types of off-label use of
medications.

An off-label prescription may include an unapproved indication, dosage,

formulation, route of administration, population, contraindication or a combination thereof
(McIntyre et al., 2000; Conroy, 2002; Neubert et al., 2004). Off-label prescribing is a widely
prevalent pharmacotherapeutic practice across many countries including the United States
1

(Chalumeau et al., 2000; Conroy et al., 2000; Pandolfini et al., 2002; Radley, Finkelstein, and
Stafford, 2006). Additionally, off-label prescribing has been found to be practiced in ambulatory
care and institutional care and in different practices settings including office-based practice
(Ekins-Daukes et al., 2004; Radley, Finkelstein, and Stafford, 2006), and hospital practice
(Turner et al., 1999; Bajcetic et al., 2005).
The extent of off-label prescribing had been shown to vary across different patient
populations. It has been estimated that the extent of off-label prescribing may be up to 40% in
adults (Brosgart et al., 1996) and 90% in pediatric patients (Conroy, McIntyre, and Choonara,
1999; Conroy et al., 2000). However, the prevalence rates of different types of off-label use
(e.g., indication-based, dosage-based etc.) in adult and pediatric patient groups differ greatly. In
children, as may be expected, the most frequent category of off-label use is dosage-based.
Studies have found dosages used in this population were both higher and lower than what was
indicated (Conroy, McIntyre, and Choonara, 1999; Pandolfini et al., 2002). Off-label prescribing
for indications other than recommended ones (indication-based off-label prescribing) has been
found to be prevalent in the pharmacotherapy of both adult (Chen et al., 2009) and pediatric
patients (Pandolfini et al., 2002).
The practice of off-label prescribing varies across drug class. Substantial variations are
observed in off-label use of different functional classes of medicines. For example, psychiatric
medicines, anticonvulsants, cardiac medicines, antiasthmatics, allergy medicines, and medicines
for peptic ulcers and dyspepsia are more likely to be prescribed off-label compared to other
medications, such as analgesics (Radley, Finkelstein, and Stafford, 2006). Off-label prescribing
was less common relatively and infrequent in medications used for glycemic control (<1%),
analgesia (6%), and in antihyperlidemics (7%). Off-label prescribing was highly prevalent

2

among cardiac medications (e.g., antianginals, anticoagulants, and antiarrythmics) (46%),
anticonvulsants (46%), asthma therapies (42%), and psychiatric medicines (31%) (Radley,
Finkelstein, and Stafford, 2006). In fact, one study found that more than 70% of patients
receiving anticonvulsant therapies were prescribed such medications off-label on the basis of
patient age or indication (Chen et al., 2005). Drug class differences in off-label use of medicines
may also vary depending on patient population. A study conducted in the UK observed that
systemic antibacterial agents were the largest category of medicines prescribed off-label,
followed by asthma therapies among all medicines prescribed off-label (based on unapproved
dose) in children in general practice (McIntyre et al., 2000).
Off-label prescribing occurs across different medical specialties (Li et al., 1998; McIntyre
et al., 2000; Haw and Stubb, 2005). Specialists may be more aware of current therapeutic
developments or have better access to clinical guidelines or information on experimental uses of
medicines through peers (Lin, Phan, and Lin, 2006). For example, the in one study it was
observed that the cardiac specialists were more likely to prescribe β-blockers off-label as
compared to the general physicians.
The extent of off-label prescribing of medicines has been shown also to vary by the intent
of the therapy and disease stage (US General Accounting Office (GAO), 1991; Brosgart et al.,
1996). For example, 68% cancer patients who were receiving palliative therapy were prescribed
at least one medication off-label compared to only 41% of the patients receiving curative care.
The proportion of the patients who received at least one medication off-label was higher in
metastatic cancer than localized cancer (GAO, 1991). However, there is no agreement in the
literature on whether the extent of off-label prescribing increases when there exists a lack of
consensus regarding the best pharmacotherapeutic option (GAO, 1991; Brosgart et al., 1996).

3

Off-label prescribing of medications has many different origins. For some disease states,
medications enter the market for very specific indications with narrow therapeutic goals. Once
in the market, these medications are tried for different off-label indications and in some cases,
off-label indications become approved indications. For example, paclitaxel, initially approved
for second-line treatment of ovarian cancer, was later approved for the treatment of breast cancer
and non-small-cell lung cancer (Boos, 2003). Aspirin was not approved until 1998 to reduce
heart attacks even though it has been prescribed by physicians for many years (O’Reilly and
Dalal, 2003). One of the most prominent examples is sildenafil, for which initial approval for
marketing was for pulmonary arterial hypertension (PAH) (Klein and Tabarrok, 2004). In fact,
some off-label use is so common that it finds a place in some official compendia. For example,
sodium valproate is listed in the British National Formulary for the treatment of mania in bipolar
affective disorder (Haw and Stubbs, 2005). Interestingly, off-label uses of some medicines
exceed their labeled uses.

For example, off-label prescriptions of rituximab showed near-

exponential growth indicating statistically significant increase in propensity of prescribing for
off-label indications compared to approved indications over time (Kocs and Frendrick, 2003).

Rationale for Off-label Prescribing
Many reasons have been cited by prescribers for using medications off-label (e.g., advice
by consultants, lack of alternatives) (Ekins-Daukes et al., 2005). In general, knowledge about
off-label use broadens a physician’s ability to relieve symptoms or cure diseases that are
refractory to standard pharmacotherapy or for which there does not exist an effective standard
therapy (Li et al., 1998). However, evidence suggests that off-label prescribing decisions may
not be always justified or, at least, are questionable. One study found that in the office-based
practice setting, medications that are prescribed off-label with lack of support include
4

gabapentin, amitriptyline, and risperidone, and with support are isosorbide mononitrate,
albuterol, digoxin, and atenolol (Radley, Finkelstein, and Stafford, 2006). Additionally, it was
observed that among all off-label uses, more cases (15%) lacked scientific evidence than those
(6%) with strong scientific evidence. This finding is supported by a review published in 2007 by
the Agency for Healthcare Research and Quality (AHRQ) that highlighted the lack of evidencebased off-label prescribing of psychiatric medications.

Implications of Off-label Prescribing
Off-label prescribing is neither illegal nor unwarranted nor always inappropriate
(Tabarrok, 2000). However, its practice may present uncertainty about safety and effectiveness
(Nightingale, 2003).

Off-label prescribing, especially in circumstances where it would be

considered inappropriate, has the potential to cause harm to different stakeholders including
patients and prescribers (Turner et al., 1999; Neubert et al., 2004).
Off-label prescribing has implications for increased cost for medication use. One study
found that in a single academic institution $1.1 million was spent between 1997 and 2001 on
rituximab prescribed off-label compared to $335,000 for FDA approved indications. However,
this figure did not include various costs incurred by patients or pharmacy preparation,
administration etc.
Professional organizations (e.g., American Academy of Pediatrics, Committee on Drugs,
2002) have issued guidelines for prescribers, who may prescribe medications off-label.
Generally, it is advocated that the decision to prescribe off-label should be based on expert
medical judgment and sound scientific evidence. Gazarian et al. (2006) recommended a decision
algorithm for evaluating the appropriateness of any proposed off-label prescribing including
differentiation between practice and research and judgment of evidence. The existence of off5

label prescribing guidelines may prove useful for ensuring appropriate use and thus, the adoption
of any such recommendations has the potential of improving off-label prescribing decisions.
However, one key to the successful application of such recommendations is the critical appraisal
of and the evaluation of applicability of evidence. Health care professionals should monitor and
evaluate off-label prescribing so that risk-effectiveness potential can be detected early. This begs
the question how can health care achieve that goal?

Opportunity for Pharmacists
It has been documented that pharmacists’ involvement in the medication selection
decision results in improvement in prescribing patterns and patient care (Lipton et al., 1992;
Hanlon et al., 1996; Finley et al., 2002). Pharmacists have provided and continue to provide a
broad spectrum of services including consultations to physicians, medication monitoring, and the
dissemination of objective information to prescribers (Pedersen, Schneider, and Scheckelhoff,
2008). Given that pharmacists have fulfilled a variety of patient care roles, how can we utilize
pharmacists’ expertise and service orientation to improve indication-based off-label use of
medicines? Do they have or perceive any role to play in that context? Two leading professional
pharmacy organizations – the American Pharmacists Association (APhA) and the American
Society of Health-System Pharmacists (ASHP) – support off-label prescribing. “The freedom
and responsibility to make drug therapy decisions that are consistent with patient-care needs is a
fundamental precept supported by ASHP” and is not believed to be limited by FDA-approved
product labeling (ASHP, 1992). ASHP also supports the role of the pharmacist to provide
medication information and clinical practice standards regarding off-label use of medications.
APhA has adopted a similar positions and policies and states that collaboration should be formed
between pharmacists and other healthcare providers to evaluate information related off-label
6

prescribing of medications. However, past studies that have examined off-label prescribing from
the perspective of pharmacy or pharmacists (Ansani et al., 2006; Stewart et al., 2007) did not
address pharmacist-level service specific to off-label prescribing.
Given that philosophy of pharmaceutical care has envisioned pharmacists as patient
advocates as well as medication experts, the objective of this study was to explore pharmacists’
perceptions of their role in off-label prescribing. Specifically, using a theory of social power
(French and Raven, 1959), the study investigated whether pharmacists were willing to influence
different types of physicians who wrote an indication-based off-label prescription on the basis of
its level of appropriateness as perceived by pharmacists. As such, the following propositions
were investigated.
P1: The pharmacist’s perceived relative expert power in relation to the physician is
positively associated with the pharmacist’s willingness to influence off-label
prescribing.
P2: The perceived appropriateness of prescription medication is negatively associated
with the pharmacist’s willingness to influence off-label prescribing.
P3: The effect of the pharmacist’s relative expert power on the pharmacist’s willingness
to influence off-label prescribing is moderated by the perceived appropriateness of
prescription medication.
P4

The effect of the pharmacist’s perceived relative expert power on willingness to
influence off-label prescribing is moderated by the perceived impact on relationship
quality with the physician as perceived by the pharmacist.

SIGNIFICANCE OF THE STUDY
Understanding off-label prescribing from pharmacists’ perspective is important for
several reasons. Off-label prescribing, if not judiciously done, has the potential of causing
detrimental effects. In situations where off-label prescribing results in harm, pharmacists along
with the prescriber may be liable for injury under conditions of negligence (Campbell, 1995). In
addition, from an ethical perspective, the pharmacist is just as much an advocate for patient well-
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being as is the physician. As such, the principles of nonmaleficence and beneficence should
oblige pharmacists to question the use of medications to ensure that patients experience the
maximum therapeutic benefit at the least possible risk of harm (Abella, 2003). Thus, off-label
prescribing has implications for pharmacists.

Although recommendations and normative

guidelines by professional organizations such as APhA or ASHP regarding the role of
pharmacists in off-label prescribing have been issued, it is important to examine whether such
normative recommendations are consistent with pharmacists’ perceptions of their role and
responsibilities.
Off-label prescribing, especially indication-based off-label prescribing, oftentimes is
driven by the physician’s perception of unmet pharmacotherapeutic needs. Once disseminated
appropriately, such uses may serve as a knowledge repository. In fact, indication-based off-label
use has been posited as a potential avenue for creating new knowledge (Demonaco, Ali, and
Hippel, 2006) in a cost-effective manner, if appropriately managed. Our understanding of the
off-label prescribing process from the perspective of pharmacists – specifically the role of
perceived power in appropriate and desirable situations – may provide us with crucial
information to help design and implement the process of reengineering knowledge.
The issue of off-label prescribing has concerned various stakeholders including
lawmakers, economists, lay public, payers, and the media. Off-label prescribing presents issues
of risk assessment and management as safety and efficacy of such use is not oftentimes well
assessed. In addition, from a societal point of view, off-label use of medications – specifically,
indication-based off-label prescribing – may not be a cost-effective treatment option, at least in
some cases. Thus, such practice has the potential to waste valuable and scant resources.
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CHAPTER 2

LITERATURE REVIEW
PRESCRIBING
Medication prescribing is one of the principal forms of treating illness (Raisch, 1996).
Prescribing behavior can be viewed as a reasoned action that is preceded by the medication
choice decision that consists of two steps. First, an evoked set – a small set of possible
treatment options, including non-drug therapies for a diagnosis – is generated. Once the
evoked set is formed, a prescriber chooses a specific therapy for a patient out of the
“available” options (Denig et al., 1990 as cited in Denig and Haaijer-Ruskamp, 1992). This
may be based on either active problem solving that involves the process of weighing utilities,
values, desirability, and expectancies of outcomes of each alternative (Segal and Hepler,
1985; Denig and Haaijer-Ruskamp, 1992) or habitual behavior, generally seen for frequently
occurring or non-life threatening disease states (Denig and Haaijer-Ruskamp, 1992).
However, medical-related outcomes such as efficacy, adverse effects, cost, patient health
status, and comorbidities as well as non-medical factors are considered when prescriptions
are written (Hemminki, 1975; Denig and Haaijer-Ruskamp, 1992; Scott, Shiell, and King,
1996).

Nonmedical factors that influence prescribing can be broadly categorized as

demographic and practice-related variables and psychosocial variables.
Demographic and Practice Variables Associated with Prescribing
Physician’s age, gender, country of training, and relationship with colleagues,
practice characteristics (e.g., number of patient seen or practice day etc.), practice setting
(e.g., HMO or hospitals) are some of the factors believed to influence prescribing
12

(Hemminki, 1975; Davidson et al., 1994; Raisch, 1996; Sleath and Shih, 2003). Differences
between general physicians and other specialties have been observed prescribing patterns of
particular groups of medications (Chin et al., 1997; Sleath and Shih, 2003) or in the treatment
of particular diseases (Freund et al., 1989; Saarela and Engestrom, 2003).
In addition, patients’ characteristics such as age (McKinlay, Potter, and Feldman,
1996; Sleath and Shih, 2003), gender (Scott, Shiell, and King, 1996), ethnicity (Daumit et al.,
2003) and socioeconomic status (Scott, Shiell, and King, 1996), insurance status (Sleath and
Shih, 2003; DeWitt et al., 2006). Such associations have been found even after controlling
for medical and nonmedical factors (Hohmann, 1989; Scott, Shiell, and King, 1996).
Interactions between physician and patient characteristics have also been noted and may
influence prescribing by physicians (Weisse et al., 2001; Hamberg, Risberg, and Johansson,
2004).
Psychosocial Factors Related to Prescribing
A host of psychosocial factors have been found to influence prescribing decisions.
Patient perceived knowledge, locus of control, assertiveness, assessment of the physician's
expert power, physician's relinquishment of control, and professional assessment of patient
requests have been proposed as antecedents that influence prescription decisions (Verbrugge
and Steiner, 1985; Krupat et al., 1999; White and Johnson, 2002). Despite objective medical
training, physicians remain human actors and become socially-conditioned to show
stereotyping either consciously or unconsciously (McKinlay, Potter, and Feldman, 1996). It
is within the framework of socio-cultural and economic influences, and biomedical
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knowledge and probabilities of outcomes, that prescribing decisions are made (Eisenberg,
1975).
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OFF-LABEL PRESCRIBING
Reasons for Prescribing Off-label
Different rationale for off-label prescribing has been cited in the literature. Despite
efforts to standardize treatment through the development and use of clinical guidelines by
professional organizations (e.g., the American College of Cardiology), lack of awareness
about appropriate use may be one of the explanations for off-label prescribing. Physicians
may not be aware that each medication in a therapeutic class may not be approved by the
FDA for the same indication(s) (Lin, Phan, and Lin, 2006). For example, among ACE
inhibitors only lisinopril has been approved for acute myocardial infarction (Radley,
Finkelstein, and Stafford, 2006). Apart from lack of awareness, some off-label prescribing
may happen because of lack of concern for such use. Prescribing of certain medications in
some indications, such as for pain management, are so well-established that clinicians may
be unaware that the medication is being used for off-label indications (Douglas-Hall, Fuller,
and Gill-Banbam, 2001). This may explain, in part why, generally, older medications are
prescribed more often for off-label indications as compared to newer medications. However,
on the contrary, Barbui et al. (2004) observed that the proportion of off-label use of second
generation antipsychotic agents were higher than that of the first generation agents.
Therefore, certain characteristics of medications (e.g., range of indications) may be
underlying factors for off-label use of those agents.
Physicians may prescribe a medication off-label because of an incorrect belief that the
medication is approved by the FDA for that use. For instance, Li et al. (1998) observed a
positive correlation between the off-label use and belief in FDA approval for a medication
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and noted that many dermatologists misidentified off-label drug/disease pairs as approved by
the FDA. However, some off-label prescribing may arise from logical extensions of FDAapproved indications. For example, certain off-label uses of antibiotics can be justified on
the basis of laboratory experiments on disease-causing microorganisms (Radley, Finkelstein,
and Stafford, 2006) although uncertainty about interactions among drugs, patients, and
comorbidities still remain.
Disease characteristics may also be associated with off-label prescribing. Off-label
medication use may occur if an existing treatment does not cure or there is a lack of
agreement in treatment. Laetz and Silverman (1991) noted that off-label prescribing is
prevalent in chemotherapy regimens for types of cancers that are more difficult to treat and is
used often in circumstances in which there are no cures, no agreement on standardized
treatment, or when treatments mainly are palliative. Similarly, a study by the US General
Accounting Office (GAO) (1991) noted that off-label usage increases generally in treating
cases that are more difficult to treat.

For example, off-label prescribing occurs in the

treatment of cancer that has advanced to a point that is no longer curable, when
chemotherapy is ineffective relatively, when patients are receiving second and third lines of
treatment, or when physicians are desperately searching for a cure or a better way to palliate
the disease (GAO, 1991). In addition, for some diseases such as non-small cell lung cancer
and cystic fibrosis, off-label uses of existing therapies are the only choice or therapy of
choice (Poole and Dooley, 2004). Physicians treating such diseases or physicians who have
needs that are not served currently by extant options may look for innovative ways to treat
their patients by applying their understanding of the disease process and/or the mechanism of
action of the medication. In fact, the physicians who claimed to have discovered off-label
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uses independent of pharmaceutical companies expressed a high need for that particular use
of the medication in their patient care (Demonaco, Ali, and Hippel, 2006).
The efficacy and safety of medications are known through controlled clinical trials or
other forms of clinical studies and medications are approved on the basis of those results.
However, in some situations it may be difficult to recruit special patient groups (e.g.,
children) to serve as study subjects. In such cases, clinicians do not feel deterred to prescribe
medications off-label.

In fact, in situations where there is less evidence available for

uncommon diseases, off-label prescribing may be more frequent (Haw and Stubbs, 2005a).
Similar problems may arise due to patients’ lack of awareness and a general unwillingness to
participate in clinical trials; combined this makes it difficult to conduct and thus generalize
the results of such trials (Institute of Medicine, 2000). In other cases, executing the clinical
trials necessary to receive new indications is not commercially viable (e.g., populations too
small or disease too rare) (Tabarrok, 2000). Therefore, some medication label use fails to
receive the necessary FDA approval and the practice of off-label prescribing persists.
Another issue that is an important consideration in off-label medication use is
polypharmacy. Oftentimes, patients have multiple conditions. As such, one medication used
to treat one condition may be contraindicated for use in patients with other comorbidities or
when used with other medications intended to treat comorbidities. However, a lack of
therapeutic options may make it difficult for physicians to avoid prescribing a medication
that is apparently contraindicated as described above. In one study that examined prescribing
behaviors using secondary data, it was found that the physicians prescribed β-blockers offlabel for health conditions for which the use of β-blockers is cautioned (Lin, Phan, and Lin,
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2006). However, it is not known if physicians systematically assess benefits/risks before
prescribing a medication off-label.
The role of satisfaction has been studied as a contributing factor for off-label
prescribing.

In a Delphi panel study, it was observed that satisfaction with available

therapies for off-label indication is less than that for approved indications (Kos, Wertheimer,
and Mrhar, 2005). Therefore, low levels of satisfaction or dissatisfaction with existing
therapies may be a reason that provides impetus to prescribe a medication off-label (Mack,
2003; Kos, Wertheimer, and Mrhar, 2005).
Factors that Negatively Affect Off-label Prescribing
The risk of adverse events and perceived threat of litigation associated with off-label
prescribing may prevent physicians from prescribing medicines off-label (Kocs and
Fendrick, 2003). The practice of defensive medicine presents an interesting paradox. The
practice of defensive medicine generally may inhibit off-label prescribing. However, such
practice may promote off-label prescribing if physicians fear legal actions for failing to
prescribe off-label in presence of published evidence (Atkins, 1998). Reimbursement by
third party payers may negatively affect off-label prescribing.

Some managed care

organizations may deny coverage of off-label indications because they consider the use
investigational or experimental (Demonaco, Ali, and Hippel, 2006). Moreover, physicians
might have to seek prior authorization for reimbursement of off-label medications. Fear of
such administrative hassles might deter physicians from off-label prescribing (Laetz and
Silberman, 1991). In recent years, the patient’s share of the cost of prescription medications
has been increasing. As a result. off-label prescribing may be negatively affected if patients
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are not willing to share the additional cost over and above that expected for medication use
according to labeling.
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Level of Evidence, Comparative Effectiveness, and Potential Adverse Effects
The existing evidence base surrounding off-label prescribing has received much
attention from researchers. Whether or not enough evidence exists for off-label prescribing
to be justifiable has also been debated. Chen et al. (2005) examined the off-label use of
anticonvulsant medications to differentiate types of off-label use on the basis of degree of
evidence in a Medicaid population. It was found that between 19% - 57% of off-label
prescribing of anticonvulsant medications was not substantiated by controlled studies. A
similar finding was made in a more recent study where it was noted that among all off-label
uses of medicines, a substantial majority (73%) had little or no scientific evidence for clinical
efficacy (Radley, Finkelstein, and Stafford, 2006). Many atypical antipsychotic medicines
are being prescribed off-label for the treatment of dementia, depression, and other psychiatric
disorders. Although off-label prescribing with limited or no support outnumbered that of
supported off-label use, it is most strikingly prevalent in psychiatry (96% of off-label use
occurred with limited or no support) (Radley, Finkelstein, and Stafford, 2006). In 2007,
AHRQ published a report reviewing evidence on efficacy and comparative effectiveness of
atypical antipsychotics prescribed off-label for the treatment of different psychiatric
disorders. The study found either no or moderate to very low evidence supporting the offlabel use of atypical antipsychotics. Specifically, there was moderate evidence for use of
riserperidone and quetiapine, low for olanzepine and no studies for ziprasidone or
aripiprazole for the treatment of obsessive-compulsive disorder. In addition, as reported by
the AHRQ review, the results from some studies conflicted that of others. For example,
olanzepine, and quetiapine showed conflicting evidence in studies that compared atypical
antipsychotics with placebo for the treatment of bipolar disorder (AHRQ, 2007).
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Additionally, an earlier review of off-label use in psychiatric medication use concluded that
although some evidence exists supporting the use of atypical antipsychotics in off-label
situations, generalization of these observations to all clinical cases might not be valid
(Fountoulakis et al., 2004). This statement may be further strengthened by the fact that many
published studies investigating the efficacy of off-label use of medications included only
small number of patients (Schelenker, et al., 2006). Moreover, when prescribers were asked
to provide the rationale for their off-label prescribing and the evidence they used while
prescribing off-label, for the majority of off-label prescriptions, physicians were able to quote
randomized controlled trials (RCTs), Cochrane Reviews, or consensus statements by expert
panels; however, in a large number of instances (41%), the level of evidence cited by the
physicians was more vague (Haw and Stubbs, 2005a).
Researchers have examined also the relationship between the off-label use of
medicines and adverse drug events. In fact, the greatest concern posed by the use of off-label
medications is the probable unanticipated adverse drug reaction (ADR) (Conroy, 2002). A
number of studies have examined the relationship between off-label prescribing and risks of
complication or adverse reactions in pediatric populations (Turner et al., 1999; Horen,
Monstastruc, and Lapeyre-Mestre, 2002; Neubert et al., 2004). In fact, many studies have
identified increased risks of adverse drug reactions associated with off-label medication use.
Horen, Monstastruc, and Lapeyre-Mestre (2002) found an increased risk of ADR was
associated with the use of off-label medications prescribed for unapproved indications,
particularly in infants. In a prospective surveillance of prescriptions in pediatric wards,
Turner et al. (1999) found a higher but nonsignificant risk of ADR associated with
unlicensed and off-label medications when compared with licensed uses and 74% of
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medications causing severe ADRs were prescribed in an unlicensed or off-label manner.
Moreover, the risk of ADR was found to be associated with the percentage of off-label use or
exposure to at least one off-label medication use event (Turner et al., 1999, Horen,
Monstastruc, and Lapeyre-Mestre, 2002). A study of pediatric outpatients observed that of
all adverse events, 42.4% were associated with the use of off-label medications and more
than 20% were associated with dose-related or indication-based off-label uses (Ulfer,
Kimland, and Bergman, 2004). Although adverse events caused by off-label and that by onlabel were not compared specifically, Neubert et al. (2004) observed a higher incidence of
ADR in the patient group prescribed off-label or unlicensed medications than in the group
treated with licensed medications.

However, whether the effect was due to off-label

prescribing or the complexities of illness was not clear.

Off-label uses of atypical

antipsychotics were associated with weight gain, sedation, extrapyramidal symptoms, and
neurological symptoms such as fatigue, headache, dizziness etc. (AHRQ, 2007).

It is

interesting to note that though elevated risk of death in elderly dementia patients treated offlabel with atypical antipsychotics was small, comparable benefits were also small and further
research is required to confirm the efficacy and safety of atypical antipsychotics prescribed
for off-label indications (AHRQ, 2007). Use of off-label dosages of atypical antipsychotics
deserves further scrutiny. While physicians’ concern for the use of these potent medicines in
elderly population is laudable, the use of low-doses may cause adverse effects and may fail to
elicit therapeutic response (Kogut, Yam, and Dufresne, 2005). Therefore, while there may be
some evidence of benefits, caution is required when medicines are used for off-label
indications. Finally, ‘fen-phen’ is a classic example that illustrates the need for vigilance
regarding the potential adverse events that may be caused by off-label prescribing.
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Fenfluramine and phentermine were approved individually for short-term appetite
suppression. However, ‘fen-phen’, the combination of the two medications prescribed offlabel, caused heart-valve disease in women (Tabarrok, 2000). Unfortunately, off-label use is
oftentimes without protocol, monitoring, or adequate long-term follow-up for ADRs.
Moreover, these ADRs may not be identified until large number of patients are affected
(Zindrick, 2000).
Is Off-label Prescribing Good or Bad?
Off-label prescribing is legal and in general, embraced by physicians and other
stakeholders including payers, health care institutions, pharmaceutical companies, and the
FDA (Nightingale, 2003). However, efforts have been made to regulate the promotion of
off-label use by pharmaceutical companies. Arguments have been made both favoring and
opposing the promotion of off-label use by pharmaceutical companies.

However,

historically, the FDA has avoided any conflict with physicians’ decisions to prescribe
medications for off-label indications or off-label in any other manner (O’Reilly and Dalal,
2003). In fact, physicians are given the freedom to lawfully prescribe medications off-label
as it is believed to provide incentives to aid patients (Cohen, 1997; Blum, 2002) and as such,
off-label prescribing may be a socially desirable behavior in some instances.

Despite

permissive laws and regulations, it is expected that caution will be exercised while
prescribing medications off-label. Though not required by law, it is considered generally
good practice to inform patients about the nature of treatment and to seek informed consent.
If a patient is injured, he or she can file malpractice claims and tort claims against the
physician for off-label prescribing or even the failure to prescribe off-label use, if
appropriate. Potential liability increases as the physician decides to or not to deviate from
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customary medical standard of care.

Therefore, continuous communication between

physicians, patients, and others in the medical community may reduce the risks of liability
(O’Reilly and Dalal, 2003). In many instances, physicians’ subjective knowledge, clinical
experience, case reports and open-label trials are the basis of off-label prescribing. While
these are valuable for directing future research, they may not constitute a sufficient basis for
treatment decisions (Hamer et al., 2002; Chen et al., 2005). In fact, it may be such that there
exists – due to lack of well-designed studies or laws or guidelines mandating clinical trial
evidence – systematic underlying biases limiting generalizability (Chen et al., 2005).
Regardless of the quality of evidence, off-label prescribing, especially of new medications,
should be based on comparative studies showing advantages in effectiveness and/or safety
and/or cost-effectiveness over existing alternatives, if any (Gazarian et al., 2006). Therefore,
off-label prescribing warrants more stringent oversight.

There is some evidence that

interdisciplinary efforts do occur; one study with specialized and small number of cases
observed that the psychiatrists consulted with pharmacists, multidisciplinary team members
and patients’ relatives while prescribing off-label medications (Haw and Stubbs, 2005a,
2005b). However, it is not known if this constitutes regular practice. Regardless of legality
of off-label prescribing, it has been suggested that physicians should carefully weigh the
benefit/risk ratio before, during, and after off-label prescribing (Torres, 1994). Even though
physicians have knowledge about patients, their medical history, and current clinical status,
they have a difficult but important job in deciding whether a specific off-label use may be
safer and more effective than all existing alternatives (Nightingale, 2003).

Rigorous

judgment, continuous evaluation, and close monitoring by healthcare professionals regarding
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off-label medication use may reduce the risks of harm, detect lack of effectiveness, ensure
early benefit, and maximize patient benefit (Dresser, 2006).
PHARMACISTS AND OFF-LABEL PRESCRIBING
Information in the published literature about pharmacist involvement in and attitudes
toward off-label prescribing is scant. Stewart et al. (2007) is one of the first known studies
investigating off-label prescribing from the perspective of pharmacy. Through a survey of
community pharmacists in the UK, the authors found that majority of community
pharmacists became familiar with the concept of off-label prescribing through their
dispensing experience. Age and dose were primary reasons that pharmacists believed that
off-label prescribing happened. Interestingly, 78% of pharmacists surveyed believed that
they have a professional duty (responsibility) to inform the physician prescribing medications
off-label. Despite this stated concern, only 39% of the pharmacists in the sample stated they
would always contact the physician if high dose of β-agonist or steroids were prescribed offlabel whereas 74% would always contact the physician if high dose paracetamol were
prescribed off-label. Ansani et al. (2006) studied off-label medication use in US academic
medical centers (AMC) to determine how many AMCs have policies regarding off-label or
‘innovative’ off-label use and beliefs about off-label or ‘innovative’ off-label medication use
as a source of problems within the AMC. Only a small number of AMC were reported to
have a policy regarding off-label use and an even smaller number of AMCs had policies
regarding innovative off-label use. Surprisingly, “problems never addressed by physicians
and pharmacists” was cited as a significant reason for the AMC not having policy. Lack of
data to support intervention, high cost, and potentially high risk/benefit ratio of the
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intervention were also cited as issues. Fewer than half of the AMCs require follow up action
and aggressive monitoring of off-label or ‘innovative’ off-label medication use.
PRESCRIBING PROBLEMS AND PHARMACIST INTERVENTIONS
In the complex process of medication prescribing and use, pharmacists are believed to
play a pivotal role.

Their role at the interface between medication distribution and

medication use process is very important for the prevention of medical errors resulting from
inappropriate prescribing. Because pharmacists represent the final point at which prescribing
problems can be identified and corrected, they can ensure that quality care is delivered to
patients (Rupp, DeYoung, and Schondelmeyer, 1992).

Moreover, due to training in

therapeutics, in the last two decades, the clinical role of pharmacists has gained prominence
and has been expanded. In fact, the pharmacists’ clinical role is acknowledged by many
professional organizations of physicians and it has been suggested that pharmacists’ expertise
in medication therapy can be utilized through collaborative medication therapy management
with physicians (Keely, 2002).

As their clinical role in managing medication therapy

continues to grow, so does their importance and ability to influence prescribing (Carroll,
2003). Moreover, it has been suggested that pharmacists may serve as educators, with
ultimate goal of optimizing patient outcomes through influencing physicians’ prescribing
behavior (Grindrod, Patel, and Martin, 2006).
Pharmacist Recommendations and Acceptance by Physicians
Pharmacists are involved in the effort and measures to optimize prescribing. Past
studies have found that pharmacists are willing to be involved in interventions related to
medication therapy and able to identify and correct prescribing problems and to influence
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prescribing in different ways (Carroll, 2003). Prescribing problems in which interventions
were made by pharmacists include inappropriate dosage and schedule, pharmacokinetic
monitoring, inappropriate combination, therapeutic duplication, inappropriate choice,
potential drug reaction and interaction, medication-use evaluation, and non-formulary
order/policy (Tamai et al., 1987; Lipton et al., 1992; Strong and Tsang, 1993; Pedersen,
Schneider, and Scheckelhoff, 2008). Physicians, in variety of settings, have generally shown
positive attitude toward pharmacist recommendations. Sulick and Pathak (1996) compared
physicians’ and pharmacists’ perceptions on the importance of various clinical activities
including patient specific recommendations of therapeutic alternatives, recommendations
based on pharmacokinetic monitoring, and patient specific suggestions to change prescribed
regimen to prevent drug interactions or adverse events. It was found that the physicians rated
the importance of general clinical activities significantly and consistently higher than did the
pharmacists.

Such a positive attitude may be reflected in the fact that the physicians

oftentimes accept and implement pharmacists’ recommendations (Leape et al., 1999; Lee et
al., 2002; Carroll, 2003). A recent national survey of US hospitals observed that the adoption
rate of pharmacists’ recommendations is highly encouraging (Pedersen, Schneider, and
Scheckelhoff, 2008).
Outcomes of Pharmacist Recommendations
It should be noted that medication use evaluation by pharmacists is likely to detect
medication errors which otherwise might go undetected; decreased medication error rates are
associated with pharmacist-provided medication information service, ADR management,
medication protocol management, and pharmacist participation on medical rounds (Leape et
al., 1999; Bond, Raehl, and Franke, 2002).
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Pharmacists’ involvement with antibiotic

prescribing has been found to result in positive outcomes with respect to medication choice,
dosage used, and appropriate utilization (Dickerson, Mainous, and Carek, 2000). Lipton et
al. (1992) found that the clinical pharmacists significantly improved the overall
appropriateness of physician prescribing, specifically, problems related with less than
optimal prescribing, no-indication prescribing, and dosage-related issues. Similarly, Lee et
al. (2002) observed that in over 30% of cases, pharmacist recommendations either improved
or resolved the problems; between 81 - 92% of cases potential harm would have been the
result if the pharmacist had not intervened. Numerous studies have been demonstrated that
pharmacist recommendations prevent medication errors and minimize adverse events
(Hanlon et al., 1996; Leape et al., 1999). Overall, pharmacist services resulted in alternative
therapy that was safer but equally effective and was associated with direct cost savings and
cost avoidance (Lee et al., 2002; Schumock et al., 2003).
COLLABORATION AND COMMUNICATION BETWEEN THE PHARMACIST
AND THE PHYSICIAN
Given the complexity of pharmacotherapeutic treatment plans, some degree of
collaboration between the physician and the pharmacist in healthcare settings is necessary in
order to provide comprehensive, efficient, and effective treatment to patients. Collaboration
is a complex and sophisticated process that includes coordination of individual actions,
cooperation in planning and decision-making, and sharing of goals, responsibilities, and
power based on knowledge and expertise among other things (Henneman, Lee, and Cohen,
1995). Many investigators have found that physician-pharmacist collaboration has resulted
in improved quality of prescribing (Spinewine et al., 2007) and improved patient care
outcomes (Boudreau et al., 2002; Borenstein et al., 2003). However, Henneman, Lee, and
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Cohen (1995) pointed out that effective communication is crucial and antecedent to effective
collaboration between the pharmacist and the physician to ensure desired patient care as
envisioned by the pharmaceutical care paradigm. However, it has also been recognized that
the practice of pharmaceutical care has the potential of causing undesirable tension or
inevitable conflict between the physician and the practicing pharmacist (Hepler and Strand,
1990). Therefore, there is a need for successful communication between physicians and
pharmacists in order for pharmacists to be able to provide the entire spectrum of activities
associated with the provision of pharmaceutical care. Although research on communication
between different actors in healthcare abounds (see Ellingson, 2002 for a review), only a few
studies (e.g., Ranelli and Biss, 2000) examined pharmacist-physician communication.
Unfortunately, although pharmacist-physician communication occurs daily, over 95% of this
activity was related to refills and less than 1% of pharmacist communication was directly
with the physician (Kallail and Stanton, 2006). Drawing on Brown and Levinson’s (1987)
conceptualization of face or social impression, Lambert (1995; 1996) investigated
determinants of pharmacy students’ and pharmacists’ decisions to communicate strategically
with physicians to protect their face. Brown and Levinson (1987) proposed three factors that
determine the weightiness of face threatening acts (FTAs) and that influence the selection of
politeness (face-saving communication) strategies. These factors are power of the person to
whom communication is targeted, social distance between the speaker and the listener, and
culture-specific ranking of the issue at hand. In other words ranking refers to the extent of
the imposition or the degree of severity of the FTA. The authors claimed that the sum of the
three factors provides an index of the weightiness of the FTA. As the weightiness of the
FTA increases, the speaker is likely to adopt more polite communication strategies. Lambert
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(1995) observed, as posited by the framework of Brown and Levinson (1987), that the culture
specific ranking of the FTA influenced the types of politeness strategy used by the pharmacy
students. Alternative medication recommendations were considered more threatening than
allergy reports and the students were concerned about taking care of the negative face wants
of the physicians (communication recipients). Lambert (1996), in a later study, found that
pharmacists made medication recommendations more politely than when they presented
allergy reports. Interestingly, some pharmacists in the study refrained from any making
recommendation in order to manage physicians’ negative face wants. However, contrary to
the work of Brown and Levinson, the author did not find support for the influence of power
and social distance on the communication strategy chosen although it was observed that
hospital pharmacists were more assertive in making recommendations than were community
pharmacists. However, Lambert (1996) recognized inadequate conceptualization of power
and the need for further study on the effect of power on communication. In a similar note,
Ellingson (2002) argued that communication among healthcare team members is likely to be,
at least partially, affected by its members’ relative power.
BASES OF SOCIAL POWER AND INFLUENCE
Social power has been conceived as the resources that impart a person ability to
influence another person to do what the former wants the latter to do (Raven, Schwarzwald,
and Koslowsky, 1998). Influence is closely related to the concept of power. In fact, the
terms power and influence are sometimes used interchangeably. However, power differs
from influence in that the former refers to the potential and the latter to the actual use of the
power. French and Raven (1959) defined influence as a force that an influencing agent (O)
can use to induce compliance by changing the beliefs, attitudes, or behaviors of a target (P)
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of influence. French and Raven (1959) originally conceptualized five bases of social power
(namely, Reward, Coercion, Legitimacy, Expertise and Reference) which have been
elaborated on and further differentiated from research and theories in cognitive social
psychology, attitude and attitude change, and organizational psychology (Raven, Schwarzald,
and Koslowsky, 1998). More recently, Raven (1992; 1993) revised and expanded the bases
of power and proposed the power-interaction model of interpersonal influence.
Reward power is defined as P’s perception of O’s power or ability to administer
positive valances and to remove or decrease negative valances. Strength of reward power
increases as the magnitude of reward and P’s perception of probability that O mediates the
reward increase. More recently, Raven (1992; 1993) classified reward power – the ability to
provide tangible rewards – as impersonal reward power and personal reward power, which is
based on P’s perception that O’s personal approval or liking of the target can be rewarding.
Coercive power, like reward power, is of two types: personal and impersonal (Raven,
1992;1993). Impersonal coercion is defined as P’s perception that O has the ability to deliver
tangible punishments for noncompliance and personal coercion refers to situation when O
threatens to disapprove or dislike P for failing to conform. The strength of coercive power is
a function of the magnitude of negative valance of threatened punishments multiplied by P’s
perceived probability of avoiding punishment by complying (French and Raven, 1959).
In its original conceptualization (French and Raven, 1959), legitimate power refers to
the power that stems from P’s internalized values dictating that O has right to influence and P
has an obligation to comply. It was conceived to consist of three bases namely, cultural (age,
intelligence, caste and physical characteristics), social structure (hierarchy), and designation.
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Legitimacy has been further elaborated into four distinct types (Raven, 1992; 1993).
Legitimate position is defined as P’s perception that O has the right to influence based on
organizational position or professional role. Legitimate reciprocity refers to P’s perception
that P has obligation to comply with O who has done something to benefit P. Legitimate
equity stems from P’s perception that P is obligated to comply in order to compensate for
inconvenience or harm caused by P to O or an effort put in by O. Legitimacy of dependence
is defined as P’s perception that P has obligation to help O who is in need of assistance.
Referent power is based on P’s identification or feeling of oneness of P with O or
desire for such an identity.

The greater the attraction of P to O, the is greater the

identification of P with O and consequently, the greater is the referent power of O. Referent
power can be positive as described above or negative in which case P prefers to disidentify
with the person seemingly unappealing or unattractive (Raven, 1992; 1993).
Expert power stems from P’s perception that O possesses knowledge or expertise in
areas relevant and interesting to P. The strength of expert power depends on the extent of
O’s knowledge as perceived by P in relation to P’s and against an absolute standard. Expert
power results in primary social influence on P’s cognitive structure. For expert power to
influence, it is required that P believes that O knows and trusts that O tells the truth. Such
conceptualization was later referred as positive expert power. There is negative expert power
when P distrusts O and does opposite of what O does or desires P to do (Raven, 1992; 1993).
Later, informational power was added to the bases of power described above.
Informational power is defined as the ability of O to present information or logical argument
to P in order to influence. Specifically, self-evident facts fit P’s cognitive structure and
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impersonal acceptance of the truth of such facts is independent of relationship between P and
O. Information can be presented in direct form and indirect form. Indirect information is
found to be especially useful when a person in low power position attempts to influence a
person in high power position (Raven, 1992; 1993).
Research on social power has yielded different typologies (Yukl and Falbe, 1991;
Peiro and Melia, 2003) in addition to that originally proposed by French and Raven. One
dichotomy that has been consistently recognized is “soft” versus “hard” power bases. A
commonsensical interpretation is that soft (weak) bases tend to be more subtle, positive, and
noncoercive while hard (harsh) bases tend to be more overt, punitive, and “heavy-handed”
(Erchul, Raven, and Ray, 2001). In other words, the soft base describes power that relies on
the influencing agent’s personal assets whereas the harsh or hard base refers to power that is
granted to the individual by the nature of his or her status (Schwarzwald, Koslowsky, and
Ochana-Levin, 2004). Within Raven’s (1992; 1993) framework of power-interaction model,
the soft base includes positive expert, positive referent, direct informational, legitimate
dependence, and personal reward power. The hard bases indicates legitimate reciprocity,
impersonal coercive, legitimate equity, impersonal reward, personal coercive, and legitimate
position power (Raven, Schwarzwald, and Koslowsky, 1998). Although little difference
exists in the pattern, other studies that utilized the IPI (Erchul, Raven, and Ray, 2001; Erchul,
Raven, and Whichard, 2001, Koslowsky, Schwarzwald, and Ashuri, 2001) provided support
that power bases can be broadly subsumed under the soft/hard two-factor solution.
STUDIES ON POWER AND INFLUENCE
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Over the years, French and Raven’s power typology has become a central concept in
the study of organizational psychology and social interactions. In the organization setting, it
has been applied to study superior-subordinate, subordinate-superior, and peer perceptions
and the use of power (Yukl and Falbe, 1991; Koslowsky, Schwarzwald, and Ashuri, 2001)
and outcomes and effectiveness of various power bases (see Podsakoff and Schriesheim,
1985 for a review). Koslowsky and Schwarzwald (1993) observed higher status individuals
such as supervisors have greater variety of power and control of resources as compared to
low status individuals. Similarly, Yukl and Falbe (1991) reported that middle level managers
had more downward power because of greater coercive power than did lower level managers
and peers recognized legitimacy, expertise, and persuasiveness were the most important
reasons for carrying out tasks. It has been contended and empirically supported that an agent
chooses particular influence strategies based on his or her evaluation of the parameters of
agent-target relationship, including the relative status of each person (Raven, 1993; Stahelski
and Paynton, 1995). In line with that argument, perceptions of relative power were measured
by other researchers (Yukl and Falbe, 1991; Somech and Drach-Zahavy, 2002). It was
observed that relative power affected superiors’ choice of strategies (Somech and DrachZahavy, 2002) and higher status person or superiors chose strategies that follow from power
bases whereas low status persons or subordinates chose influence tactics involving less
control of resources (Stahelski and Paynton, 1995).
In the health care setting, perception of power, use of power, and outcomes of such
uses have been examined. To influence hospital personnel, infection control nurses in US
hospitals who were high in self-efficacy were more likely to report using informational and
expert power and nurses with low self-efficacy legitimate and coercive power (Raven,
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Freeman, and Haley, 1982 as cited in Raven, 1992). Manfredi (1996) examined the role of
power in the leadership activities by nurse managers. Nurse managers reported the use of
legitimate power in situations that required upholding standards, enforcing policies, and
hiring, firing, or disciplining staff, expert power to bring about change, and referent power
when they sought cooperation and agreement. While exercising referent power, the nurse
managers asked for support from staff and communicated that they are valued and important.
Past research reported that information, expertise, position and dependence legitimacy, and
referent power were the top-rated power bases recognized by both hospital and nursing staff
and their supervisors and there was a high congruence in compliance perception between the
two groups (Raven, Schwarzwald, and Koslowsky, 1998; Koslowsky, Schwarzwald, and
Ashuri, 2001). Physicians had used expert power to influence nurses (Raven, Freeman, and
Haley, 1982 as cited in Raven, 1992). It has been suggested that informational power and
referent power, if used by physicians, may be very effective in gaining patient compliance
(Erchul and Raven, 1997).
Pharmacists’ power and influence has also been studied in the organizational context.
Pharmacists’ power may have multitude of sources. For example, pharmacists may have
requisite expertise and be in the best position to analyze and evaluate the medications for
formulary decisions (Balu, O’Connor, and Vogenberg, 2004) or pharmacists may be a
member of subcommittees acting as a facilitator between the P&T committee and the
subcommittee (Nair, Coombs, and Ascione, 2004). Pharmacists on the P&T committee
exerted substantial power over formulary decision-making although pharmacists’ sources of
influence were not investigated (Mannebach et al., 1999; Bagozzi, Ascione, and Mannebach,
2005). Using French and Raven’s typology, Arntson (2002) observed that the bases of power
35

that were considered the most important determinants of the pharmacist’s influence on
formulary admission decisions included expert, information, and referent power. However,
the importance of sources of power was found to vary by the number of members on the
P&T committee.

Pharmacists’ expert and information power were found to be most

influential in large committees while expert and referent power in smaller committees
(Arnston, 2002). Thus, the growing importance of P&T and pharmacists’ role in the P&T
and other related subcommittees may give pharmacists a sense of power. Such sources of
influence may be grouped under what Raven (1992; 1993) described as third party influence.
Social power bases have been applied in context of school teacher consultation.
There have been arguments about which social power bases are most relevant to teacher
consultation.

Reviewing published studies that applied French and Raven’s original

conceptualization of power, Erchul and Raven (1997) concluded that there is some evidence
that expert power and referent power are linked to school teacher consultation. Erchul,
Raven, and Ray (2001) made further investigation of school psychologists’ perceptions of
power based on the new conceptualizations. The authors concluded that consultants viewed
informational power and expert power, together labeled as credibility, to be most effective
and more likely to be used. Researchers has also examined if both the consultant and the
consultee held similar views of the effectiveness of the consultant’s use of power (Erchul,
Raven, and Whichard, 2001). Even though both the consultant and the consultee viewed
direct informational and positive expert power to be more effective, the authors cautiously
concluded that both parties share similar views about the effectiveness of social power in
consultation when more global indicators are considered, but hold divergent views when
more specific indicators are considered. Although the use of certain power bases may be
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perceived effective by both the consultants and the consultee, it becomes effective in reality
only if those powers are applied when attempting to influence. Recently, Wilson (2008)
studied likelihood of the use of power bases unlike previous studies that focused on
perceived effectiveness of power bases (Raven, Schwarzwald, and Koslowsky, 1998; Erchul,
Raven, and Whichard, 2001). As such, consultants were more likely to use soft than harsh
power bases. Specifically, direct information power, positive expert power and referent
power are significantly more likely to be used. Getty (2006) concluded that likelihood of
using soft bases, in general, is positively related – specifically, each of the three power
described above was positively and significantly related – to consultants’ self-perceptions of
effectiveness. Finally, Lippitt et al. (1952) concluded individuals with high attributed power
tend to initiate more social influence attempt than low power individuals.
LIMITATIONS OF STUDIES
PHARMACISTS’ ROLE

ON

OFF-LABEL

PRESCRIBING

AND

Off-label prescribing, if not judiciously done, has the potential of causing detrimental
effects. In situations where off-label prescribing results in harm, pharmacists along with the
prescriber may be liable for injury under conditions of negligence. One way to mitigate such
liability is by assuring the appropriateness of such use. Consultation with the prescriber in
order to determine the rationale, documentation, as well as review of current scientific and
professional literature, and applying critical professional judgment may minimize such
liability (Campbell, 1995). In addition, from an ethical perspective, the pharmacist is just as
much an advocate for the patient’s well-being as is the physician.

Principles of

nonmaleficence and beneficence oblige pharmacists to question the use of medications,
certainly those used off-label, to ensure the medication offers maximum therapeutic benefit
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to patients at the least possible risk of harm (Abella, 2003). Therefore, off-label prescribing
has strong implications for pharmacists. Yet, past research regarding off-label prescribing
inadequately examined issue from the perspective of pharmacists. It has been found that
pharmacists have been consulted in some instances regarding off-label prescribing (Haw and
Stubbs, 2005a).

However, other studies examined opinions and beliefs about off-label

prescribing only (Ansani et al., 2006; Stewart et al., 2007). Moreover, the results of these
studies are not generalizable in other hospital practice settings because of the sampling
design and because research subjects who practiced in community pharmacies or teaching
hospitals.
Physicians consider indication and effectiveness of a medicine as the two most
important of the ten parameters of appropriate medication prescribing (Samsa et al., 1994).
However, while studying community pharmacists Stewart et al. (2007) focused on pediatric
off-label prescribing where off-label prescribing occurs largely due to unapproved
population, dosage, and formulation. Indication-based off-label prescribing deserves special
attention because of inherent risk; however, existing research has failed to provide much
needed information about this issue.
It has been reported that indication-based prescribing is prevalent in AMCs.
However, only half of the AMCs require Pharmacy and Therapeutic Committee (P&T)
review of policy on off-label or innovative off-label use (Ansani et al., 2006). It is largely
unknown about off-label prescribing and the policies that govern that activity in community
hospitals because this has not yet been examined in that context.
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Leape et al. (1999) observed that pharmacists took responsibility to ensure safety
identifying unsafe conditions and need for process improvement. Whether pharmacists go or
are willing to go through the same deliberation in case of indication-based off-label
prescribing has not been studied. Pharmacists have been often envisioned as professional
best positioned to make sound decision and judgments concerning medication therapy.
Flood and Scott (1978) argued that for optimal functioning, professional groups must be in a
position to exercise power largely, compared to other groups, over decisions concerning their
sphere of competence. Campagna (1995) argued that although pharmacists performing at
prescriptive and consultative levels may significantly influence prescribing, few pharmacists
are performing at corrective level of decision-making and even fewer in prescriptive and
consultative level. Under the light of such findings, how pharmacists who are providing
clinical services influence off-label prescribing merits attention. Campbell (1995) suggested
that if the pharmacist is not convinced of the appropriateness of the off-label use of
medications, a decision not to comply with the physician’s decision would be proper course
of action. However, whether pharmacists providing clinical pharmacy services are willing to
influence prescribers in the context of inappropriate off-label prescribing is not yet known.
Ellingson (2002) argued that communication among health care team members is
affected by power, hierarchy, and privilege within the specific hospital or other health care
institutions. However, social power and its impact on pharmacist-physician communication
have not been investigated well.

Although power has been conceptualized as

multidimensional construct (French and Raven, 1959), past research (Lambert, 1996)
conceptualized and examined power as one-dimensional construct. While it is evident that
pharmacists possess some power (Arnston, 2002), Lambert (1996) examined only
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pharmacists’ perception of physician’s expert power - neither relative perception of power
nor the other bases of power. Relative perceptions of power in the context of off-label
medication product selection and use may affect willingness to/ likelihood of communication
or influence. In addition, it is not known whether perception of power and its effect on
pharmacists’ decisions to influence has changed since Lambert examined pharmacistphysician communication more than a decade ago; given the way the scope of pharmacy
practice has evolved in the last few years, there is the potential for these relationships to be
different.
In sum, in the context of indication-based off-label prescribing, there exists a need for
investigation on attitude and perceived roles and responsibilities of pharmacists providing
clinical pharmacy services in community hospitals. Specifically, it is worth examining the
effect of perceived social power on pharmacists’ intent of influence concerning indicationbased off-label prescribing.
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CHAPTER 3
CONCEPTUALIZATION, RESEARCH METHOD, AND TECHNIQUES
CONCEPTUALIZATION
The following describes the psychological process of assessing power and its
potential and the preparation for influence attempts.

The power/interaction model of

interpersonal influence (Raven, 1992) provided the foundation for the conceptual framework
(Figure 1) for this study of pharmacist power and willingness to influence. The model can be
used to study power-influence dynamics from both the agent’s perspective as well as the
target’s perspective. The model provides a process view of power and influence attempts
and describes various antecedents to and consequences of power and influence attempts.
Figure 1: PROPOSED CONCEPTUAL FRAMEWORK
Control Variables
• Assessment of social power
• Information
• Referent
• Legitimate power of dependence
• Attitude
• Perceived responsibility
• Perceived relative expert power
• Perceived appropriateness

Willingness to
influence
- Perceived impact on
relationship quality

Adapted from Raven (1992)
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The influencing agent, within the context of this study, the hospital pharmacist,
assumed a motivated and rational person, assesses the power bases that may be available to
use as well as how effective those power bases will be in implementing changes. The
argument for the assessment of power appears to be intuitive as the influencing agent may
have multiple influence strategies available for use and the choice of a particular influence
tactic would be based on his or her evaluation of power over the target (Fung, 1991). The
influencing agent’s assessment of power inherently is relative in nature. Researchers have
found empirical evidence of the effect of relative power on influence behavior (Somech and
Drach-Zahavy,

2002).

Because

both

physicians

and

pharmacists

train

in

pharmacotherapeutics and share the domain of knowledge relevant for medication use,
perception of relative power – at least for some power bases (e.g., expert power) that are
relevant to the shared domain – is an appropriate representation rather than absolute
perception.

As such, this approach was thought to capture appropriately the hospital

pharmacist’s assessment of power.
Once the assessment of power is completed, the influencing agent will evaluate the
potential of influence. The influencing agent may carry out a cost-benefit analysis of the
influence strategy. It can be argued that such analyses are influenced critically by various
factors such as personal norms and values, secondary gains and losses, and time, costs, and
effort required for achieving the desired outcomes (Raven, 1992). Here, the influencing
agent may consider the potential relational, situational, and/or ethical ramifications of using a
particular power base (Getty, 2006). For example, the influencing agent might ask if the use
of a seemingly effective power base affects relationship or if it is ethically and professionally
appropriate in a given context.
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After having assessed the available power bases and costs and benefits of their use,
one would expect that at this point the agent might prepare for the influence attempt (Raven,
1992). This preparation for influence attempts can manifest itself in several ways. For
example, the influencer can enhance (e.g., displaying diplomas or degrees) or emphasize
(e.g., showing expertise or advanced knowledge for expressing expert power) activities that
support his or her power position. However, before the agent decides to enhance or prepare
the stage for an influence attempt, it can be argued, the agent must decide that s/he is going to
influence. Such a decision may be accentuated by favorable appraisals of power bases and
potential outcomes.

In other words, the agent’s willingness to influence precedes the

preparation for an influence attempt. This argument appears valid for three reasons. First,
because of the differential nature and sources of various power bases, different types of
power may need different stage-setting requirements, attributes, and tools. Willingness to
use different bases of power may dictate specific preparations for influence attempts. For
example, for legitimate power of reciprocity, an influencing agent might try to evoke
ingratiation and describe how one favored the target on previous occasions. Second, factors
such as personal preferences or attributes may affect the use of power.

For example,

infection control nurses who perceived themselves competent were more likely to use expert
and information power (Raven, Freeman, and Haley, 1982 as cited in Raven, 1992). In
school consultation, gender was associated with the likelihood of use of different power
bases (Wilson, Erchul, and Raven, 2008). Finally, having a power base available indicates
neither that the agent will attempt to influence or prepare for the attempt nor does it mean
that it will be an appropriate means of influence. However, having power may increase the
willingness to influence. Kipnis (1972) found that individuals with more power attempted to
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influence their workers more frequently in comparison to low power individuals. Based on
the finding, the author concluded that delegated power might encourage one to exert
influence. Similarly, albeit in a different context, Lippitt et al. (1952) observed that attributed
power was consistent with self-perceived power and recipients of attributed power made
frequent influence attempts.

Therefore, it can be argued that the influencing agent

deliberates over using particular bases of power before he or she finally prepares for the
influencing attempt. In other words, willingness to influence is the necessary intermediate
step between the assessments of relative power bases and the preparation for influence
attempts.
While Raven (1992) clearly identified the role of cost-benefit implications on
influence attempts, the variables and the relationship between the assessment of power and
attempt to influence were not elucidated. However, it may be argued that such variables may
moderate the effect of power on willingness to influence for several reasons. First, an
influencing agent’s decision to invoke some power may be affected by individual
preferences, situational attributes, or disadvantages and advantages of using power bases.
For example, the agent, as argued by Getty (2006), may decide not to use a seemingly
potential and available power base because of the potential for an adverse outcome.
Additionally, Raven (1993) echoed the same possibility that the use of direct form of
information power may result in a disastrous interpersonal relationship problem. Second, if
the agent has had previous experience, it may affect self-perception of power, perception of
effectiveness, and cost of influence attempts (Raven, 1992). In other words, experience may
affect the decision to invoke power. However, even in situations where the influencing agent
does not have experience, it can be contended, the influencing agent – as a rational being –
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will assume and prospectively assess the effects of such an influence attempt. Furthermore,
the use of different bases of power has been found to be associated with differential
perceived effectiveness and outcomes (Raven, 1992; Wilson, Erchul, and Raven, 2008). This
evidence supports the argument that potential or perceived outcomes of influence attempts
may affect one’s willingness to influence.
Building on the findings of previous research as summarized in Table 1 and Raven’s
(1992) power/interaction model of interpersonal influence, it can be posited that the
assessment of power bases affects the agent’s willingness to influence and a number of
relational, situational, and contingency variables moderate the relationship between power
and willingness to influence. For the sake of parsimony and relevance to this research, the
relationship between pharmacist’s relative expert power and willingness to influence and the
moderating effect of perceived impact on the interprofessional relationship quality were
examined.
Table 1: Select studies on power, use of power, and influence
Authors
Lippitt et al. (1952), Kipnis (1972)
Erchul, Raven, and Whichard (2001),
Koslowsky, Schwarzwald, and Ashuri
(2001), Wilson, Erchul, and Raven (2008)
Raven (1992)

Summary of findings
Power and influence attempts are positively
related
Soft power bases are more effective and
more likely to be used
Assessment of power bases is antecedent to
influence attempt

The extant literature on pharmacists’ influence on prescribing (as described in
Chapter 2) supports the thought that the perception of inappropriateness of a prescription by a
pharmacist is positively associated with the decision to influence prescribing. However, in
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case of off-label prescribing with inadequate evidence, the pharmacist may believe that the
physician may have special reasons and knowledge or may possess adequate information
supporting that choice of therapy. Such a case can also be considered analogous to what
Brown and Levinson (1987) described as ranking. That is, asking a physician about the
rationale of a prescription with low evidence may constitute a greater face threatening act to
the physician than that with high evidence depending on the expertise of the physician. As
the ranking of the act increases, the communicator’s propensity to choose more polite
communicative strategies increases with abstention from communication being the most
polite strategy available (Lambert, 1995). The propositions described below are based on the
previously mentioned rationale and have been described in the proposed conceptual
framework (Figure 1).
P1:

The pharmacist’s perceived relative expert power in relation to the physician is
positively associated with the pharmacist’s willingness to influence off-label
prescribing.

P2:

The perceived appropriateness of prescription medication is negatively
associated with the pharmacist’s willingness to influence off-label prescribing.

P3:

The effect of the pharmacist’s relative expert power on the pharmacist’s
willingness to influence off-label prescribing is moderated by the perceived
appropriateness of prescription medication.

P4

The effect of the pharmacist’s perceived relative expert power on willingness
to influence off-label prescribing is moderated by the perceived impact on
relationship quality with the physician as perceived by the pharmacist.

VARIABLE OPERATIONALIZATION AND MEASUREMENT
Dependent Variable
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Willingness to influence
Willingness to influence was the dependent variable in the study. Willingness to
influence was defined as the pharmacist’s willingness to initiate action with the physician in
order to ensure rationale for an indication-based off-label prescription, perceived
inappropriate by the pharmacist. In other words, willingness to initiate action with the
physician implies a willingness to intervene using rationality tactic. Research focusing on
influence has considered different tactics or elements of a complex array of influence forms
that are used by the agent on the target to achieve the agent’s desired goals (Erez and Rim,
1982; Kipnis, Schmidt, and Wilkinson, 1980; Schriesheim and Hinkin, 1990; Yukl and
Falbe, 1991). A synthesis of the influence literature revealed three categories of influence
behavior: hard strategy (e.g., assertiveness), rational strategy (e.g., rationality; bargain), and
soft strategy (e.g., friendliness; ingratiation; norms of reciprocity) (Kipnis and Schmidt,
1985). With a rational strategy, the agent appeals to or tries to invoke instrumental reasoning
on the part of the target and presents himself/herself as knowledgeable and credible in order
to evoke a positive response (Farmer et al., 1997). For example, the influencing agent may
offer a course of action that is supported with logic (evidence) and is consistent with the
influence attempt in order to improve the expected utility or outcome that is important to the
target of influence. Although rationality is used more in cases of influence in the upward
direction, it is viewed as socially acceptable for influence attempts in other directions as well
(Yukl and Tracey, 1992) and has fewer costs associated with it than other influence tactics
(Kipnis, Schmidt, and Wilkinson, 1980). Therefore, it is appropriate to examine the use of
rationality by pharmacists regardless of the fact that the pharmacist-physician relationship is
not like a subordinate-superior relationship, rather a consultant-consultee dyad, although it is
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widely believed that physicians enjoy more privilege than pharmacists in healthcare
organizations.

Finally, whereas political norm structure may vary within an institution

regarding what types of upward influence attempts are considered acceptable (Allen et al.,
1979), the use of reasons and logic seems to be almost universally accepted as an appropriate
means of influence tactic (Farmer et al., 1997).
To date, the influence typology offered by Kipnis, Schmidt, and Wilkinson (1980)
has received substantial attention in psychology literature (Schriesheim and Hinkin, 1990;
Yukl and Falbe, 1991; Yukl and Tracey, 1992). Subsequently, Schriesheim and Hinkin
(1990) presented an improved version of the typology and offered an empirically validated
instrument.

This 18-item instrument was comprised of six dimensions (ingratiation,

exchange of benefits, rationality, assertiveness, upward appeal, and coalition) of influence
strategy. The authors compared the 18-item scale with other potential shortened versions
(e.g., a 27-item instrument) of the typology. Although Schriesheim and Hinkin (1990)
suggested that the 18-item scale had superiority over the other versions, for this study, the
four items from 27-item scale classified under the rationality subscale were adapted in order
to measure willingness to influence using rationality. The four items consistently loaded
under the rationality subscale in different studies (Schriesheim and Hinkin, 1990). The
subscale showed internal consistency of 0.74 and test-retest reliability and the correlation
between the rationality subscale and social desirability was not significant (Schriesheim and
Hinkin, 1990).

These four items were believed to capture adequately willingness to

influence that may require one to use both verbal and written forms of communication that
are common in pharmacist-physician communication within the hospital.

In addition,

consistent with the measurement of other latent variables, a global measure of willingness to
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intervene was added. The participants were asked to indicate their level of agreement about
their willingness to intervene and their willingness to use the rationality tactic using a 7-point
scale where 1 = not at all willing and 7 = absolutely willing. This response task followed
immediately the exposure to the off-label prescription order scenario.
Independent Variables
Perceived relative expert power
The pharmacist’s positive relative expert power was examined in the present study.
Expert power is task oriented and decision-specific and depends on personal rather than
organizational resources (Koslowsky, Schwarzwald, and Ashuri, 2001). Expert power is
accepted universally as a means of influence. In previous studies in educational psychology
and organizational attitudes, expert power has been found to be effective (Erchul, Raven, and
Whichard, 2001; Koslowsky, Schwarzwald, and Ashuri, 2001; Raven 1992). Arnston (2002)
found that expert power was the most important determinant of the pharmacist’s influence on
the P&T committee.
Pharmacists provide professional services to physicians within their sphere of
competence and expertise (pharmacotherapy). Pharmacists collaborate with physicians in
order to provide such services. Therefore, it can be argued that pharmacist-physician dyad is
similar to other dyadic relationships (e.g., school consultant-consultee) where power bases
are utilized for influence attempts.

However, unlike other contexts, pharmacists and

physicians share a domain of knowledge and skill.

As a result, conceptualization of

pharmacist perception of relative expert power was considered appropriate and relevant in
the context of the study. The pharmacist’s relative positive expert power was defined as the
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extent to which the pharmacist perceived to possess expertise and knowledge in a relevant
area relative to that of the physician. Pharmacist relative expert power was operationalized
as perceived power differential between the pharmacist and the physician described in the
study. There were two experimental groups of pharmacists with high and low relative expert
power. The pharmacist’s relative expert power was believed to be high or power differential
low when compared to a general practitioner with less knowledge and experience; the
pharmacist’s relative expert power was believed to be low or power differential high when
compared to a specialist physician with more knowledge and experience.
Perceived appropriateness
Physicians may prescribe medications off-label; however, it is expected that they will
have a reasonable expectation of therapeutic success that is supported by sound scientific
evidence (Henry, 1999). Concerns for quality of care arise when evidence for use is not
clear, is not sufficient, or is not well documented. Such prescribing practice with some
rationale but inadequate evidence, occasionally termed as innovative off-label prescribing,
becomes challenging when prescribing is not considered clinical research (Ansani et al.,
2006). In the context of clinical practice, indication and effectiveness are considered most
important among different parameters of prescription medication appropriateness index
(Samsa et al., 1994).

Effectiveness is closely related to safety and efficacy that are

determined based on the strength and quality of scientific evidence. For example, little or
sparse empirical data, anecdotal evidence, or methodologically flawed study designs are
considered poor quality and weak evidence. Perceived appropriateness was operationalized
as the extent to which the pharmacist perceived the medication as appropriate for the offlabel indication based on the strength and quality of evidence. There were two categories –
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“more” and “less” – of appropriateness of evidence supporting the off-label prescription.
The more appropriate category (referred to in this project as off-label) had stronger and better
quality evidence supporting the use of the drug for the specified off-label indication than the
less appropriate category, termed in this project as experimentation.
Moderating Variable
Perceived impact on relationship quality
It has been discussed that a rational agent considers multiple factors including
consequential impact of influence before making a decision to influence. Therefore, it can be
argued that the pharmacist might weigh the impact of an influence attempt on the relationship
with the physician before the pharmacist becomes willing to influence. More specifically,
the impact on relationship quality may become critical to such intent.

Developing,

managing, and evaluating relationships within the context of dyadic transaction and
voluntary participation has been studied well in the marketing literature. More specifically,
relationship quality (RQ) and relationship management have received a great deal of
attention. RQ has been empirically investigated in the domain of buyer-seller, distributormanufacturer, and service provider-customer relationships (Crosby, Evans, and Cowles,
1990; Mohr and Speckman, 1994; Kumar, Scheer, and Steenkamp, 1995; Leuthesser, 1997;
Dorsch, Swanson, and Kelly, 1998). RQ is a higher-order multidimensional construct that
consists of different positive relationship outcomes reflecting overall strengths of a
relationship and the extent to which it fulfills the needs and expectations of the parties
involved in the relationship (Smith, 1998). However, there exists a lack of agreement on
dimensions of RQ.

For example, Crosby, Evans, and Cowles, (1990) proposed two
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dimensions of RQ: satisfaction and trust. Smith (1998) conceptualized that RQ manifests, in
the context of buyer-seller relationships, at least in three constructs namely, trust,
commitment and satisfaction.

Drawing upon a large number of studies in relationship

marketing, Roberts, Varki, and Brodie (2003) proposed that RQ in the domain of a customer
relationship with a service providing firm had five dimensions: trust in provider’s integrity
and benevolence, affective commitment, satisfaction and affective conflict and concluded
that RQ predicted behavioral intention and subsumed service quality. RQ is determined
partly by key facets of relationship management (Smith, 1990). Relationship management
has been defined as the extent to which parties possess the behavioral tendency as well as
orientation to actively cultivate and sustain close working relationships (Crosby, Evans, and
Cowles, 1990). Among various aspects of relationship management, communication has
received consistent attention from researchers and has been observed to affect trust,
commitment, and satisfaction (Anderson and Weitz, 1989; Anderson and Narus, 1990;
Smith, 1990). Other researchers have posited communication as key driver of or antecedent
to RQ (Roberts, Varki, and Brodie, 2003). Indeed, communication quality, assessed as
formal and informal interaction between members of the dyad, has been considered a
dimension of a scale that measures RQ from a firm’s perspective (Lages, Lages, and Lages,
2005).

Finally, a study conducted with community pharmacists explored the nature of

pharmacists’ perceived relationship quality with physicians within the context of
pharmacists’ participation in interprofessional healthcare team (Dobson et al., 2006).
Though not theoretically grounded, the relationship scale administered in the study had items
that appeared to capture, at least in part, trust, satisfaction, communication, and commitment.
In this study, perceived impact on relationship quality was defined as the extent to which the
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pharmacist believed that the influence attempt would affect the pharmacist’s relationship
with the physician with respect to trust, commitment, communication, satisfaction, and
affective conflict.

Affective conflict was thought appropriate to measure because

pharmacists might believe that the physician might perceive an influence attempt as
encroachment on the domain of prescribing that is controlled by physicians. Unfortunately,
no single scale exists that adequately captured all the dimensions considered relevant for the
current study. Therefore, it was thought appropriate to adapt items from different studies that
adequately captured all the relevant dimensions of RQ. Items were adapted from Dobson et
al. (2006), Roberts, Varki, and Brodie (2003), and Morgan and Hunt (1994). The scale from
Dobson et al. (2006) has been applied in the context of physician-pharmacist relationship.
Scales used in the three studies showed adequate reliability (>0.79) and factor loadings of the
items under their intended factors were satisfactory. Two items were included that measured
attitudinal and affective commitment. Three items measured communication (information
sharing and recommendation providing).

For measuring trust, two items were used to

measure credibility of pharmacist and his or her service. Additionally, items measuring
affective conflict (two) and satisfaction (two) were adapted from Roberts, Varki, and Brodie
(2003). Items measured the level of agreement with each statement about the perceived
impact of influence attempt on relationship quality using a 7-point scale ranging from 1
(strongly disagree) to 7 (strongly agree).
Control Variables
Control variables were related to other power bases and internal factors that might
affect a pharmacist’s decision to act. While discussing the power/interaction model, Raven
(1992) proposed that motivational factors were important for exerting influence and choosing
59

influence strategies. The motivational factor may be related to factors that satisfy internal
needs. As such, the control variables included in this study were pharmacists’ referent
power, information power, and legitimate power of dependency, perceived responsibility,
and attitude.
Other bases of power
In previous studies in educational psychology and organizational attitudes including
the study of attitudes of nurse supervisors and nurses working in hospitals, the three power
bases – direct information power, positive referent power, and legitimate power of
dependency – along with expert power have been consistently grouped under the soft base of
the soft/hard power dichotomy (Erchul, Raven, and Ray, 2001; Erchul, Raven, and
Whichard, 2001; Koslowsky, Schwarzwald, and Ashuri, 2001; Raven, Schwarzwald, and
Koslowsky, 1998). Like expert power, these three bases of power were task relevant and
sought compliance through personal resources rather than organizational resources
(Koslowsky, Schwarzwald, and Ashuri, 2001). In addition, expert power may be strongly
related or share a common source with referent power and information power. For example,
the agent’s expertness may come from his/her experience, which may increase the target’s
desire of identification with the agent. Thus, experience may be associated with expert
power and referent power. A physician’s referent power may have a halo effect that may
work against pharmacist’s expert power (French and Raven, 1968). Similarly, the content of
communication and acceptance of validity of the content are closely related – the former
comes from information power and the latter comes from expert power. The underlying
factor for power of dependence may be the identification of the need for knowledge-driven
assistance. In sum, it can be argued, these three bases and expert power may operate
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simultaneously or in tandem. Additionally, Arnston (2002) concluded that in addition to
expert power, information power and referent power were significant determinants of the
pharmacist’s influence on the P&T committee.

Therefore, these three bases of power,

measured as general attributes, were controlled such that the effect of expert power could be
examined. The pharmacist’s direct information power was defined as the extent to which
he/she perceived to have access to and control over relevant information and had logical
argument in relation to that of a physician. The pharmacist’s legitimate power of dependence
was operationalized as the extent the pharmacist perceived that a pharmacist had obligation
to help a physician and a physician was dependent on the pharmacist. The pharmacist’s
perception of physician’s referent power was defined as the extent to which the pharmacist
identified with a physician and had regard for the physician’s qualities.
Although social power has been conceptualized not as the objective ability of the
agent to influence but rather as the perception of the target of the potential ability of the
agent, measures of pharmacists’ self-perceived power were considered in this study for
several reasons. First, self-perceived power generally reflects good measure of attributed
power and was strongly and positively related with attributed power (Lippitt et al., 1952).
Second, attribution may underrepresent actual power if the target is not aware of multiple
sources of power that the agent may have but may not use or use effectively (Simon, 1953).
Therefore, the agent may still intend to influence based on evaluation of power bases without
the target being able to attribute until significant outcomes are achieved (El-Ansary and
Stern, 1972). Third, self-perceived power seems to be more relevant in the study of one’s
willingness to influence. Thus, assessing pharmacist self-perceived power was considered
consistent with the goal of the proposed research.
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To measure pharmacists’ self-perceived referent power and legitimate power of
dependency, items were adapted from the Interpersonal Power Inventory (IPI), (Raven,
Schwarzwald, and Koslowsky, 1998).

The instrument measures the expanded

conceptualization of the power bases proposed by the power/interaction model of
interpersonal influence (Raven, 1992). The IPI appears to be a reliable instrument, with
coefficient alpha ranging from 0.62 to 0.93 and coefficient alpha for both soft bases and hard
bases greater than 0.80 (Erchul, Raven, and Ray, 2001; Schwarzwald, Koslowsky, and
Allouf, 2005). The instrument showed satisfactory convergent validity when analyzed with
multiple approaches and superior discriminant validity (Koslowsky, Schwarzwald, and
Ashuri, 2001). The instrument was considered appropriate to examine pharmacist-physician
power relationship because this relationship conceptually is similar to the school
psychologist-teacher relationship as pharmacists and school psychologists provide
consultation services to physicians and teachers respectively. The operationalization of the
information power subscale in the IPI was not applicable in the context. Pharmacist’s
relative information power was operationalized on the basis of the pharmacist’s perceived
reasons for selection and access to and control over information in relation to that of a
physician. Five items were used measure information power. As a result, a thirteen-item
scale was designed to measure pharmacist direct information power, positive referent power,
and legitimate power of dependency. Pharmacists’ level of agreement about possessing
those power traits were measured on a 7-point scale where 1 = strongly disagree and 7 =
strongly agree.
Perceived responsibility in off-label prescribing
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The professional responsibility for ensuring safe and effective pharmacotherapy is
shared by physicians and pharmacists. In fact, there exists the need to maintain and extend
interprofessional safeguards and oversight to ensure the delivery and quality of
pharmaceutical care to patients (Rupp, DeYoung, and Schondelmeyer, 1992). Pharmacists –
due to a unique set of professional perspectives and skills – may make valuable contributions
to appropriate off-label prescribing in cases when they perceive their responsibility in the
process. This argument stems from the relationship between responsibility and behavior.
Role theory asserts that perceiving responsibility might imply action (Levinson, 1959). Felt
responsibility has received attention in the organizational psychology literature and has been
associated with employees’ extra-role behavior (Pearce and Gregersen, 1991). Krebs (1970)
noted subjective feelings of responsibility were a precursor to altruistic acts. Planas et al.
(2005) found that community pharmacists perceived responsibility for drug therapy outcomes
were associated with direct patient care behavior of the pharmacists. In the one known study
that investigated off-label prescribing in the hospital setting, pharmacists were reported to
delegate the responsibility of issues related to off-label prescribing to the IRB (Ansani et al.,
2006) and may seek to justify their action or lack of action regarding the issue. As a result, it
is appropriate to posit that perceived professional responsibility plays a role upon one’s
intention to act or behavior.
Incorporating philosophical, moral, legal, and psychological components of
responsibility, Schlenker et al. (1994) proposed the triangle model of responsibility (TMR)
that provides an integrated and clear view of responsibility. The TMR consists of three
elements: prescriptions (e.g., rules, norms, expectations), events (e.g., actions and
consequences), and identity images (roles, qualities, commitments) that can vary in relevance
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or importance to the actor or the observer (Schlenker et al., 1994).

The TMR posits

responsibility as the direct function of strengths of three links – prescription-event, eventidentity, and identity-prescription – as perceived by the person making evaluation. The links
describe if a clear set of prescriptions exist that have relevance to the actors and actors have
resources to act and to control events or outcomes. Researchers empirically tested the TMR
in multiple studies and in different contexts including pharmacy and the relationships
proposed in the model, in general, were supported (Schlenker et al., 1994; Britt, 1999; Planas
et al., 2005). Pharmacists’ perceived responsibility was operationally defined as the extent of
responsibility perceived by the pharmacist in the evaluation of off-label prescribing. The
items to measure perceived responsibility were adapted from Schlenker et al. (1994). The
four items loaded under the responsibility factor and were found to have a theoretical basis.
Perceived responsibility was measured on a 7-point scale ranging from 1 (strongly disagree)
to 7 (strongly agree).
Attitude
Attitude toward indication-based off-label prescribing was measured was also
included as a control variable. Attitude has been defined as "a psychological tendency that is
expressed by evaluating a particular entity with some degree of favor or disfavor" (Eagly and
Chaiken, 1993, p. 1). Therefore, it may be argued that favorable or unfavorable opinions
about off-label prescribing may influence a pharmacist’s decision to act. Generally, it has
been found that an attitude has three components: cognitive, affective, and behavioral
processes (Breckler, 1984). However, attitudes can be formed or expressed primarily or
exclusively based on any one of the three components or some combinatory of the three. A
cognitive-affective-behavioral analysis is considered as providing a convenient terminology
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for analyzing differing aspects of attitude expressions (Eagly and Chaiken, 2007). The
cognitive component refers to beliefs or thoughts about an attitude object. For example, a
pharmacist may believe that off-label prescription is not safe. The affective component
refers to feelings or emotions associated with an attitude object. For example, a pharmacist
may express that they feel bad while dispensing an off-label prescription. The behavioral
component refers to past behaviors or behavioral intentions with respect to an attitude object.
For example, a pharmacist may not want to get involved with off-label prescription fearing
negative experience with an off-label prescription. For this study, attitude was defined on the
basis of the three components of attitude as described above. Semantic differential has
become a popular method for measurement of attitude (Himmelfarb, 1993) and the
intercorrelations among the various bipolar adjectives are sufficiently high such that few
bipolar scales result in sufficient reliability (Heise, 1970).

However, for the sake of

appropriate operationalization and ease of interpretation, a 4-item, 7-point Likert-type scale
(1=strongly disagree, 7=strongly agree) was used to measure attitude.
Communication effectiveness
Given the context of interprofessional interaction, the assessment of one’s own
interpersonal communication disposition is important as it may affect the decision to act.
Broadly speaking, communication competence reflects the impression or judgment about
one’s own ability to manage interpersonal interaction (Rubin and Martin, 1994). While the
conceptualization of communication competence, generally considered a multidimensional
construct, is debated, effectiveness and appropriateness are universally accepted as important
dimensions (Spitzberg, 2003).

Appropriate communication implies whether the

communication behavior meets specific situational and relational norms and obligations.
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Effective communication, perceived by some scholars as necessary and sufficient condition
for competence, is about accomplishing one’s goals or other desired objectives. Evidence
suggests that people perceive themselves competent when they were successful in achieving
their goals (as cited in Canary and Spitzberg, 1987). Thus, an effective communicator has
the ability to handle conflict situations and solve issues in a cooperative manner (Rubin and
Martin, 1994). Communication effectiveness was measured with three items. The items
were drawn from the environmental control subscale of the Interpersonal Communication
Competence Scale (Rubin and Martin, 1994). While the scale has reported an acceptable
reliability, the subscale has relatively less reliability.

However, the scale is appealing

intuitively and has strong face validity (Spitzberg, 2003). In addition, the developers have
suggested that the subscale is an appropriate measure of communication effectiveness in
compliance-gaining situations, consistent with its use in this context. Pharmacists were
asked to respond to the three items using a 7-point response format where 1 = never and 7 =
always.
Demographic variables
In additional to the control variables, several demographic characteristics of the
pharmacists in the sample were captured. Time spent on clinical activities, educational
background, gender, age, experience, and hospital type were collected in order to describe
the study population.
Research Design
A 2X2 between-subjects design (Table 2) was used where pharmacist’s relative
expert power measured as perceived power differential based on physician attributes and
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appropriateness of the prescribed drug were the two factors. Subjects were provided a
scenario that offered one of two different physician profiles manipulating the perceived
power differential between the pharmacist and physician. Additionally, the scenario
described a prescribed medication that varied on the degree of appropriateness (off-label and
experimentation) of use in the described medical conditions.
Table 2: Research Design
Degree of Appropriateness
More
Less
(Off-label)
(Experimentation)

Between Subject Factors
Power differential based
on physician attributes

High (Specialist)

X11

X12

Low (Generalist)

X21

X22

Experimental Procedure
Four vignettes (Appendix A) were developed for use in this study. Scenarios were
designed to describe a situation where a hospitalized patient received an order for a
medication (fluoxetine) from a physician. The scenarios described the disease and relevant
patient characteristics (e.g., age) that would be considered necessary for the evaluation of the
patient’s treatment plan. Each scenario described an order for a medication that could be
categorized into one of the two groups on the basis of the degree of appropriateness:
indication based off-label use with suitable evidence (off-label) and indication-based offlabel use with no/very minimal evidence (experimentation). Such manipulation was based
on the use of the medication in different off-label indications (diabetic neuropathy and
fibromyalgia) and corresponding degree of evidence described in Drugdex®. In other words,
each pharmacist evaluated one of the combinations of medication order: 1) fluoxetine in
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fibromyalgia (off-label) or 2) fluoxetine in diabetic neuropathy (experimentation). An actual
medication name was used in order to simulate a realistic situation. In addition, using this
approach would allow pharmacists the opportunity to verify indications for the drug in case
they desired to do so as this was not a prohibited activity on the part of the respondents. The
order was written by a physician who practiced in the hospital. However, all scenarios
mentioned that the physician had been practicing in the hospital for the last two years in
order to control for social distance (Lambert, 1995). In the scenarios, pharmacist relative
expert power was manipulated based on perceived power differential created by describing
the physician’s attributes such as knowledge, experience, expertise, and practice specialty
(specialist or generalist) of the physician (Table 3).
Table 3: Physician profile: high power (specialist) vs. low power (generalist)
Generalist

Specialist
Dr. Smith is a rheumatologist and
highly recognized expert in the
field of rheumatology. Dr. Smith is
considered
an
extremely
knowledgeable physician with
extensive clinical experience. Dr.
Smith has 20 years of experience of

Dr. Smith is a general practitioner. Dr.
Smith has 5 years of experience of
clinical practice.

The combined effect of all of these attributes was believed to create differences in
perceptions of pharmacist’s relative expert power. Following confirmation that the subject is
practicing as pharmacist in a hospital, the subject was randomly assigned to one of the four
groups that were formed based on the specialties of physicians and appropriateness of
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medication orders. Subjects were asked to respond to the questions on information power,
referent power, and legitimate power of dependence with reference to physicians in their
hospital. Subjects were also asked about their communication behavior and beliefs about and
roles in off-label prescribing. Then, a scenario was presented to the pharmacists. Following
exposure to the scenario, participants were asked to imagine that they were working as
pharmacist in the situation and received the order for their approval. Then respondentpharmacist was asked to respond to a battery of questions measuring the remaining variables
of interest.
Sampling Design
The sample for this study was obtained from membership rolls of state affiliates of
the American Society for Health-System Pharmacists (ASHP). The ASHP state affiliates
were contacted to seek access to their members. The sampling frame of membership lists of
participating affiliates can be considered, at least for practical purposes, a nationally
representative database of pharmacists practicing in hospitals in the United States. As noted
earlier, the study aimed to examine the effect of pharmacists’ self-perceived power on
willingness to influence inappropriate off-label prescribing. As such, it is possible for any
pharmacist to play the hypothesized role in off-label prescribing. However, pharmacists
involved in clinical activities and involvement in direct patient care activities are more likely
to encounter such prescribing situations. Moreover, a large number of hospitals in the U.S.
follow a model of integrated pharmacy practice (Knapp, Blalock, and Black, 2001).
Consistent with such practice, “clinical” pharmacy was operationalized based on time spent
providing clinical pharmacy services and/or direct patient care services. Bond et al. (2001)
operationalized clinical pharmacists as those who spend 50% or more time providing clinical
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services.

However, this definition appeared to be too restrictive for the current study.

Existing evidence suggests that, on average, approximately 28% of pharmacists’ time is spent
on clinical pharmacy services (Knapp, Blalock, and Black, 2001). Pharmacists practicing in
small hospitals may spend even less time on clinical services (Guerro, Nickman, and Bair,
1990). A recent survey reported that 14.1% and 37% hospitals had pharmacists spend less
than 10% and 20% of their time monitoring medication therapy respectively (Pedersen,
Schneider, and Scheckelhoff, 2007). As a result, for this study, attention was paid to recruit
an adequate number of pharmacists who spent 10% or more of their time on clinical
pharmacy services or direct patient care. This was thought to be consistent and appropriate
with the goal of examining pharmacists’ perception of off-label prescribing. Additionally,
this study sought to include pharmacists practicing in community hospitals.

There are

several reasons for examining off-label prescribing in community hospitals. First, academic
hospitals are likely to follow different working protocols than do community hospitals, as
clinical trials are more likely to be conducted in academic medical centers (AMC) than they
are in community hospitals. As a result, pharmacists perceived roles and responsibilities may
be different in AMCs compared to those in community hospitals. Second, AMCs are likely
to have an IRB that may be charged with handling off-label use of medications. As a result,
pharmacists have the opportunity (or responsibility) to delegate the issue to the IRB (Ansani
et al., 2006b). Finally, the number of community hospitals is larger than that of AMCs.
Although anecdotal evidence suggests that off-label prescribing is as prevalent in community
hospitals as in AMCs, how community hospitals address off-label prescribing has never been
studied. In addition, adequate representation of pharmacists who identified themselves as a
clinical pharmacist was ensured.
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Sample Size
This study was powered to detect the effects of social power and appropriateness on
the pharmacist’s willingness to act.

This approach was believed to be appropriate for

pragmatic reasons (e.g., sample size) and primary research interest. Using the ANCOVA
option in G*Power (version 3) with an input of medium effect size and 80% power, it was
determined that 179 usable final responses would be required in order to conduct analyses
(approximately 45 per group). However, it can be noted that this number of responses
appears to be sufficient for analyses – including the analysis with the moderating variable –
according to the rule-of-thumb for sample size suggested by Green (1991).
SURVEY INSTRUMENT DESIGN
A survey instrument (Appendix B) was designed to elicit responses on the variables
that were studied. The questionnaire began with a short description of off-label prescribing.
Then items measuring information power, referent power, and legitimate power of
dependence with reference to physicians were placed.

Items measuring pharmacist’s

communication effectiveness, perceived responsibility in off-label prescribing, and attitude
toward indication based off-label prescribing were placed afterward.

A scenario that

described physician specialty and a medication order was presented.

Questions were

developed and asked to collect information on 1) if they are willing to influence the
physician for the drug perceived as prescribed off-label in an inappropriate manner, 2)
perceived impact of influence attempt on relationship with physician, 3) self-perceived
relative expert power, 4) appropriateness of use, and 5) demographic information. The
aforementioned order was followed to ensure appropriate and adequate utilization of
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information and logical order.

For example, following the exposure to the scenario,

questions on willingness to influence were asked to ensure maximum utilization of
information presented in the scenario. Then, questions on perceived impact on relationship
quality and manipulation checks on self-perceived relative expert power and appropriateness
of use were asked.
Pretesting the Survey Instrument
Before executing the survey and after obtaining the approval from The University of
Mississippi’s IRB, questionnaires were pretested with Pharmacy Practice faculty,
professional students, and graduate students in the Department of Pharmacy Administration
at The University of Mississippi. Based on feedback, necessary changes were made in order
to improve interpretability and readability of the questionnaire. Finally, two of the state
affiliates (smaller affiliates) that agreed to facilitate the distribution of the survey to hospital
pharmacists were requested to distribute the questionnaire to their members. A group of 10
hospital pharmacists who reported to be practicing in hospitals situated across a few states
participated in the pretest. Results of the pretest provided assurance that manipulations were
working as expected. Thus, pretesting questionnaires with the actual subjects improved the
interpretability, hence reliability, of the questionnaire.
Manipulation check
A manipulation check was conducted to determine if the pharmacist’s perceived
relative expert power manipulation was successful.

Effort was made to create a large

difference in the perception of power of the physician. To measure the manipulation of
pharmacists’ self-perceived relative expert power, items from the expert power subscale from
72

the IPI (Raven, Schwarzwald, and Koslowsky, 1998) were adapted.

A 4-item scale

(APPENDIX B, Q2.12) measured the manipulation of relative expert power on a scale of 1
(strongly disagree) to 7 (strongly agree). In addition, the manipulation of the perception of
appropriateness of the prescription order was examined. Perception of appropriateness of the
medication order was examined using a two-item 7-point scale (1= not at all appropriate, 7=
very appropriate) (APPENDIX B, Q2.13) for the medication order in the scenario.
DATA COLLECTION
A self-report survey methodology was used for data collection. Data were collected
using the Internet. This method of data collection is convenient, efficient, and relatively
inexpensive (Ileva, Baron, and Healey, 2002).

Moreover, it may be convenient for

respondents to reply while at work. The survey was administered using the online survey
software provided by Qualtrics. This study adopted a facilitated distribution approach for
data collection. First, an email cover letter (APPENDIX C) that contained the link to
questionnaire was sent to the state affiliates who agreed to participate in the study (see
APPENDIX D for the initial communication requesting access to members). Then, the state
affiliates were requested to resend the cover letter and link to their pharmacist members.
Based on the geographic location of the completed responses, some of the ASHP state
affiliates were sent a second request to distribute the survey invitation. The state affiliates
were request to distribute a reminder cover letter and the link to their membership
approximately 7 days from the time it was reported that the first contact survey invitation
was sent.
DATA ANALYSIS
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Data were analyzed using statistical software SPSS 17. Descriptive statistics analyses
were performed to examine the characteristics of the respondents. Reliabilities (Cronbach’s
alpha) of all the multi-item scales used in the study were examined. Factor analysis on
control power bases was conducted to examine whether the items loaded under the
hypothesized factors.

Similar analyses were performed on the scales for measuring

willingness to influence, perceived impact of influence attempt on relationship, perceived
responsibility, and attitude.
T-tests were performed to examine if relative expert power and appropriateness
manipulations were successful. The subjects in the specialist physician group were expected
to rate power differential higher (low relative expert power of pharmacist) than those in the
generalist group. Hypotheses were tested using the ANCOVA analyses where relative expert
power and appropriateness were independent variables.

In the ANCOVA analyses,

perceived responsibility, attitude toward off-label prescribing, other three power bases, and
communication effectiveness were covariates.

In addition to the main effects of the

independent variables, interaction between relative expert power and appropriateness and
that of expert power and impact of influence attempt on relationship quality were examined.
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CHAPTER 4
DATA ANALYSIS AND RESULTS
As was described in Chapter 3, the sampling frame for the study came from the
membership rolls of state affiliates of the American Society of Health-System Pharmacists
(ASHP). These membership rolls included practicing as well as nonpracticing (e.g., retirees)
pharmacists. Among practicing pharmacist members were those who reported presently to be
working in hospitals, retail settings, long-term care, and other health care settings.

When

contacted, 25 state affiliates agreed to forward the survey invitation to their membership.
Because of pretest procedures, 23 affiliates were expected to distribute to its membership the
survey invitation that contained a link to the Internet survey. One state affiliate was reported to
have posted the invitation request on its website only. Of the remaining 22 affiliates that agreed
to distribute the survey invitation, 17 reported to have distributed the survey. As such, there
remains a possibility that five of the affiliates that agreed to forward the request for participation
failed to do so. Consistent with the stated objectives of the study, only pharmacists reported to
be currently working in the hospital setting were allowed to participate in the study. Although
the study was planned initially as an evaluation of nonacademic community hospitals, it became
necessary to include responses from pharmacists practicing in academic hospitals as well.
However, consistent with the objective of including pharmacists with at least some clinical
duties, extra responses were collected above and beyond the predetermined target of 180
responses. A total of 238 respondents completed the survey and 29 participants provided partial
responses such that their responses could be included in the study (information on demographics
was entirely incomplete or partially complete). Thus, 267 responses were available for analysis.
Table 4 describes the number of respondents in each group.
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Table 4: Number of Respondents in Experimental Groups
Degree of Appropriateness
More
Less
(Evidence-based (Experimentation)
Off-label)

Between Subject Factors

Power differential based High (Specialist)
on physician attributes
Low (Generalist)

70

68

63

66

As was mentioned in a previous chapter, the survey was conducted through facilitated
distribution. Although it is ideal to report response rate, it was not possible to do so because of
non-availability of the number of participants who received an email contact along with the link
to survey questionnaire (affiliates were not willing or not able to provide this information to the
principal investigator). In the interest of full disclosure, it can be noted here that a large number
of potential respondents started the survey but did not complete it. A total of 395 respondents
were assigned to one of the four experimental groups by the questionnaire software (Qualtrics).
However, over 100 potential respondents stopped their participation prior to being exposed to the
experimental condition.
SAMPLE DEMOGRAPHY
Respondent Characteristics
Table 5 summarizes the characteristics of the pharmacists included in the study. Among
respondents who provided demographic information, there were 126 male pharmacists and 134
female pharmacists respectively. The average age of the respondents was 44.18 years with a
average hospital practice experience of 17.9 years. One hundred and sixty two pharmacists
reported to have earned a Pharm.D. degree and 50 pharmacist-respondents reported to hold at
least one BPS specialization. On average, respondent pharmacists spent 21.67% and 38.55% of
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hours worked per week on distributive activities and clinical/ direct patient care services
respectively. Thus, respondents devote a substantial part of their weekly hours on clinical
pharmacy-related services.
Table 5: Respondents Demographics
Characteristics

Mean

Std. err.

Male

N (%)
126 (47.2)

Age

44.18

0.77

260

Education*
B.S (Pharmacy)
Pharm.D.
B.S (Pharmacy) & BPS
Pharm.D. & BPS
Pharmacotherapy specialization among those with BPS

94 (34.2)
116 (43.4)
11 (4.2)
46 (17.2)
36 (72)

Job title
Staff pharmacist
Clinical pharmacist
Pharmacy manager/ director
Multiple descriptions
Other

35 (13.4)
80(30.7)
63 (24.1)
46 (17.6)
24 (9.2)

Experience
Present hospital
Total hospital practice
Average percentage of time spent per week
Distributive
Clinical/ direct patient care
Administrative
Other
* Categories are not mutually exclusive

11.49
17.89

0.64
0.77

249
250

21.67
38.55
29.99
9.19

1.70
1.95
2.13
1.21

250
249
250
247

Respondents were asked also to describe their current job; pharmacists could identify themselves
as having multiple job titles. One hundred and twenty four pharmacists identified themselves as
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clinical pharmacists, 55 as staff pharmacists, 31 as pharmacy managers, 45 as pharmacy
directors, 10 as consultant pharmacists, and 38 as other (part-time retail, residency, faculty,
clinical faculty, informatics). However, a majority (nearly 70%) of pharmacists who exclusively
chose to be identified as other were devoting 20% or more time to direct patient care or clinical
services. As described in Table 5, a large number of pharmacists identified themselves solely as
a clinical pharmacist.

Altogether, respondents represent a group, which is composed of

pharmacists who follow an integrated pharmacy practice model (Knapp, Blalock, and Black,
2001), pharmacists with exclusively clinical duties, and administrators who may have better
ideas about hospital policies.
Hospital Characteristics
Information about the hospitals where respondents currently practice was collected
(Table 6). Hospitals were distributed across all four geographic regions (as classified by the U.S.
Census Bureau) with the largest group (41.6%) of them being located in the South. Over 50% of
these hospitals were described as private not-for-profit community hospitals. Additionally, a
majority of the hospitals in which respondent pharmacists are employed have an IRB but no
policy regarding off-label prescribing.
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Table 6: Respondents’ Hospital Characteristics
Characteristics

N

%

Geographic region
Northeast
Midwest
South
West
TOTAL

82
25
111
30
248

30.7
9.4
41.6
11.2
92.9

Hospital is an academic medical center
TOTAL

111
250

41.6
93.6

Type of ownership
Private community hospital (not-for-profit)
Private community hospital (for-profit)
Public community hospital
Federal hospital
University hospital
Other
TOTAL

136
21
24
11
49
9
250

50.9
7.9
9.0
4.1
18.4
3.4
93.6

Hospital with an IRB
TOTAL

208
249

77.9
93.3

Hospital with policy on off-label prescribing
TOTAL

110
250

41.2
93.6

N.B., total represents number of participants responded to the question.

Group Comparisons on Characteristics
As was described in Chapter 3, study participants were randomly assigned to one of the
four experimental groups. Therefore, the groups can be expected to be similar with regard to
important demographic characteristics. Because attrition rate was high before and after group
assignment, groups were compared to determine if differences between the experimental groups
occurred. ANOVA analysis was performed to examine if groups differed in the distribution of
age, pharmacy practice experience, and clinical duties. No differences were found among the
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experimental groups on these characteristics; however, a difference (p=0.014) was found among
the groups when experience in their present hospital was evaluated.

Pharmacists in the

generalist-low appropriate group showed the highest experience (mean=13.7 years, s.d.=11.4) in
present hospital, followed by those in the specialist-high appropriate group. These two groups
also showed the largest variance in response patterns. The lowest mean was observed for the
generalist-high appropriate (mean=9.01 years, s.d.=8.8) group, which is also the smallest cell.
Considering unequal variances and cell sizes, experiences in present hospital did not appear to be
significantly different as revealed by post-hoc comparisons (Dunnett T3 (p=0.07); GamesHowell (p=0.06)). It can also be argued that although experience in present hospital may give
familiarity with policy and influence working relationships, there may be a ceiling effect;
whereas total experience may play a role in perceiving expert power differential – a variable of
principal interest. Therefore, it was believed that a difference in experience in their present
hospital would not affect significantly the results from subsequent analyses. Similarly, cross
tabulations (chi-square) were run to determine differences between groups in the distribution of
gender, job title, hospital ownership status, AMCs, hospital type, existence of IRB and off-label
policy, and education. No significant differences with respect to these variables were observed
among experimental groups. Although number of subjects having any BPS specialization was
significantly (p<0.05) low in the generalist low appropriate group, no such difference was
observed on having a pharmacotherapy specialization, which represents the largest category
(>90%) of BPS in the respondents participating in the survey. Thus, it was believed that the
experimental groups were similar.
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Anomalies in Responses
Before analyzing data for inferential purposes, inspection of response patterns or
‘consistency checking’ (Singleton and Straits, 2005, p. 478) was required. In other words, an
evaluation was undertaken in order to determine if responses to questions are intuitive or are
related to those of other questions in a reasonable manner. Each case was thoroughly inspected
for each variable and each dubious case was flagged. Six such cases were identified and reasons
are presented in Table 7 along with any action taken. In addition, response patterns on item 8
through item 11 of the impact on relationship quality scale (IRQ) were examined. The purpose
of the scale was to examine perceived negative outcomes associated with a pharmacist’s action.
Responses on IRQ were recorded on a 7-point scale (1=not at all; 7=absolutely). It can be noted
here that if either of item 8 (angry) or item 9 (annoyed) is greater than 4 then both item 10
(content) and item 11 (happy) should be less than 4 and vice versa. However, responses on all
these items can be on the lower side of the scale simultaneously, meaning that the respondent is
not much concerned or concerned at all. Based on the argument, 23 cases, which include 4 cases
already flagged, were identified for which responses on IRQ were considered incompatible and
reclassified as missing data (Singleton and Straits, 2005).
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Table 7: Inconsistency in Responses
Questions/ Case #
Reasons/ Action
Scale Item
Items from
31
All 1s (willingness to influence < -1.96 of standardized values of the
multiple
DV) - flagged
variables
76
Q2.5.1 onwards all are 5s, Q2.3.5 and q2.3.8 (both are 4), Q2.3.6,
Q2.4.2, and Q2.4.3 (all are 6s), q2.4.1 is 3, and the rest are 5s - flagged
100
All 7s except Q2.4.1 to Q2.4.3 all of which are 4s - flagged
173
Q2.3.4 is 4 and Q2.5.1 onwards all are 4s and the rest are 5s
225
All 7s except Q2.3.5 that is 6 - flagged
232
All 7s- flagged
IRQ
*Bold
values are
incompati
ble
in
pairs
(1sttwo vs.
2nd two)

23, 65
43
71
82
89
107
109
114
123
152
162
206
222
226
246
256

6, 6, 6, 6– recoded as missing
6, 5, 6, 6– recoded as missing
6, 6, 5, 4– recoded as missing
3, 6, 5, 4– recoded as missing
5, 5, 5, 5– recoded as missing
3, 5, 5, 5– recoded as missing
4, 5, 5, 5– recoded as missing
4, 5, 6, 6– recoded as missing
5, 5, 4, 5– recoded as missing
5, 5, 3, 5– recoded as missing
1, 5, 4, 5– recoded as missing
6, 7, 5, 3– recoded as missing
2, 5, 5, 4– recoded as missing
4, 5, 6, 5– recoded as missing
2, 6, 6, 6– recoded as missing
4, 5, 4, 5– recoded as missing

Manipulation Checks
Pretest results provided an initial indication that the manipulation of the independent
variables (expert power differential and appropriateness) were working as expected. However,
due to an inadequate number of responses available in the pretest, it was not possible to conduct
statistical analyses to verify that assertion. To ensure that the experimental manipulation was
working as conceived, several statistical tests (t-tests) were performed. Respondents were asked
if they believed that the physician described in the vignette had more expert power – measured
by average of responses on a four-item 7-point scale – than did the respondent. It can be noted
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here that the four-item measure loaded under a single factor as conceptualized and reliability of
the scale was acceptable (Cronbach’s alpha = 0.877). The results (Table 8) that excluded flagged
cases showed that pharmacists assigned to the specialist physician group rated the physician’s
relative expert power significantly higher (p<0.001) as compared to participants in the generalist
group. However, in general, pharmacists in both groups rather somewhat disagreed on a great
power differential between pharmacists and the physicians described in the study as indicated by
the average ratings that are less than 4 (4=’neutral’). This result may be a reflection of the
clinical acumen of the pharmacists in the sample. A large number of respondents held advanced
practice degrees (e.g., Pharm.D.) and spent a significant portion of their work-related activities
on clinical functions.
In addition to evaluating power differences, pharmacist respondents were asked about the
appropriateness of the medication in the disease condition as described in the scenario.
Appropriateness was measured as mean of two items. As expected, respondents in the low
appropriate group rated the off-label use significantly (p<0.001) less appropriate than did the
pharmacists in the high appropriate group. The results for both manipulations did not change
when either all cases were included or all cases identified in Table 7 were excluded.
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Table 8: Manipulation Checks
Group

N

Mean
Sig (p)
(Std.err.)
Specialist
135
3.68 (0.13) <0.001
Relative expert power of physician
Generalist
126 3.12 (0.09)
Evidence-based (high)
131 5.29 (0.10) <0.001
Appropriateness
Experimentation (low)
130 3.55 (0.11)
N.B., higher number means higher power of physician or appropriateness; flagged cases

EXAMINATION OF MEASUREMENT SCALES
Although scale items of almost all variables appear in the published literature, the
population and the context of this study were different from those studies. As suggested by
Churchill (1979), factor analyses (principal axis factoring (PAF)) were performed on the
variables measured by scale items to determine if they loaded on the factor as conceptualized.
Reliabilities (internal consistency) of multi-item scales were then estimated.
Dependent Variable
The dependent variable (DV), willingness to influence, was measured by five items. The
descriptive statistics of the DV have been presented in Table 9. The distribution of the DV was
negatively skewed such that the mean values of each group were above 5 on a 7-point scale.
However, 95% of values lay between ±1.96 of standard deviation.
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Table 9: Descriptive Statistics of Willingness to Influence (N=267)
Statistic
Overall scale mean and std. error

Value
5.54 (0.082)

Skewness

-1.072

Kurtosis
1.085
Between-group homogeneity of variance –
0.302
Brown-Forsythe test (p)
Reliability (Cronbach’s alpha)
0.929
N.B., Estimates include cases that are flagged.

Considerable debate exists over appropriateness of factor analysis model in a specific
context (Hair et al., 2006). The scale measuring the DV had already been applied (Schriesheim
and Hinkin, 1990) and its factor structure was confirmed. Thus, the objective of factor analysis
here was to reassess the latent dimension in the context of the study; common factor analysis was
thought appropriate as suggested by Hair et al. (2006). The factor analysis (PAF) of the five
items of the DV (loadings >0.8) loaded strongly under a single factor as expected. Reliability
(Cronbach’s alpha) was 0.925 excluding six flagged cases. The reliability estimate did not
change meaningfully when those cases were included.

All inter-item correlations were

significant (p<0.01) and ranged from 0.627 to 0.801. All item-to-total correlations were 0.767 or
greater. It was concluded that the willingness to influence scale was reliable and was suitable for
use in subsequent analyses (Hair et al., 2006; Peter, 1979).
In addition to willingness to influence, the survey instrument contained a three-item scale
to measure a distinct, yet related, concept, likelihood to act. The scale appeared to be reliable
(Cronbach’s alpha 0.863) with all item-to-total correlations greater than 0.60. Although the
measure of willingness to influence was adapted from past research and well validated,
considering different context and population construct validity it was examined further. If the
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measure is valid, it should correlate with a measure of a theoretically-related concept (Singleton
and Straits, 2005). The correlation between likelihood to act and willingness to influence was
0.569, which is significant at the 0.01 level. However, pairwise correlations of the variables
(items) of the willingness to influence scale with the variables of the likelihood to act scales were
lesser than correlations among within-scale variables of willingness to influence. Thus, the
measure of willingness to influence provided evidence of construct validity (Churchill, 1979;
Churchill and Surprenant, 1982).
Covariates and Moderator
While developing the instrument (IPI) Raven, Schwarzwald, and Koslowsky (1998) used
Principal Component Analysis. However, in this study common factor analyses (PAF) of the
covariate power variables were performed to examine the factor structures of the IPI because of
the argument (i.e., reassessing factor structure) presented above and results are displayed in
Table 10. The items measuring power of dependence loaded strongly under a factor without any
cross-loadings that are greater than 0.3. Referent power items were not good as evidenced from
poor loadings (less than 0.5) except for one item with a factor loading greater than 0.7.
Surprisingly, information power items loaded under two factors. Three items loaded strongly on
a single factor with no large cross-loadings. In the present analysis, percentage of variance
extracted by the first factor was slightly higher (10.61% vs. 9.49%) than the second factor.
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Table 10: Factor Analysis of the Covariates and Moderator with Varimax Rotation
Scale

Item

Power of
dependence

Referent power

Informational power

IRQ**

Q.2.3.1
Q.2.3.2
Q.2.3.3
Q.2.3.4
Q.2.3.5
Q.2.3.6
Q.2.3.7
Q.2.3.8
Q.2.3.9
Q.2.3.10*
Q.2.3.11*
Q.2.3.12*
Q.2.3.13
Q.2.11.1
Q.2.11.2
Q.2.11.3
Q.2.11.4
Q.2.11.5
Q.2.11.6
Q.2.11.7
Q.2.11.8
Q.2.11.9
Q.2.11.10*
Q.2.11.11*

Factor
1
0.784
0.869
0.551
0.793

2

3

4

5

6

0.322
0.770
0.714
0.676
0.893
0.722
0.707
0.930
0.899
0.884
0.934
0.940
0.890
0.930
0.754
0.732
0.447

0.783
0.825

N.B. * items are reverse coded. Only factor loadings > 0.3 in absolute value were
presented. ** Run on data that excluded incompatible responses. All estimates excluded
flagged cases.

As was described earlier in the text, the moderating variable IRQ contained some
responses that could be considered incompatible. As such, an additional analysis was undertaken
where these cases were classified as missing. As opposed to the a-priori conceptualization, IRQ
emerged as two factors. First, nine items loaded on a single factor while two items loaded under
another factor with a small cross-loading of one item (loaded more heavily under the first factor).
It can be noted that the first factor extracted a very large amount of variance (67.68%) while the
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second factor extracted only 13.15% of variance. Hair et al. (2006) suggests that a solution that
explains 60% of the total variance can be considered satisfactory in some cases.

While

consistent with a-priori conceptualization, the one factor solution was believed to be appropriate
as it would capture variance sufficiently and be parsimonious as well. In addition, dropping the
last two items may alleviate the response pattern issues as described previously. Factor analysis
was run again on the abbreviated IRQ scale and the single-solution factor extracted 80.55% of
variance. It should be noted that the results did not change meaningfully when all cases were
considered.
After examining the factor structures of the various measures, reliability estimates were
examined. The results are presented in Table 11. The reliability estimate of the power of
dependence scale was 0.867. All inter-item correlations ranged from 0.411 to 0.814 and itemtotal correlations from 0.518 to 0.844. The reliability estimate of referent power was poor
(0.394) and thus not acceptable (Hair et al., 2006). In addition, inter-item correlations (<0.3) and
item-total correlations (<0.4) were not high. Thus, it is concluded the scale measuring referent
power was not reliable and was not included in subsequent analyses. When five items were
considered together, the information power scale had a reliability of 0.679 which is not
satisfactory (Hair et al., 2006). However, two items had low item-to-total correlations of 0.207
and 0.329. Moreover, these same two items loaded under a different factor when factor analysis
was performed. The item-total correlations for the remaining three items were between 0.472
and 0.62. While deleting the item with the lowest item-total correlation would improve the
scale’s reliability (0.723), the other item still showed poor item-total correlation (0.162).
Although it may be tempting to conclude that the information power measure has an underlying
two-factor structure, the original conceptualization does not support this interpretation (Raven,
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Schwarzwald, and Koslowsky, 1998). Moreover, unidimensionality should be ensured before
reliability is established (Gerbing and Anderson, 1988). It can be noted here that although the
two items causing concerns possessed face validity (they appear very close to what is potentially
captured by expert power (e.g., physician has better explanation)), past research has shown
empirically that expert power and information power are correlated (Raven, Schwarzwald, and
Koslowsky, 1998). In that case, retaining the two items may remove some variance from expert
power that it jointly shares with the DV and information power and reduce the efficiency of
ANCOVA analysis (Miller and Chapman, 2001).

On the other hand, if the three-item

information power scale is adopted, the reliability estimate becomes 0.825. Having a measure
with high reliability may also serve to satisfy – at least, partially – an assumption of ANCOVA
(i.e., covariates are measured without error). Therefore, for the sake of parsimony and consistent
with the theory and measurement practice, information power was measured as a single factor
with three items.
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Table 11: Reliability Estimates of the Covariates and Moderator
Scale
Power
Power
of
dependence
Referent
power
Information
power
Communication
effectiveness

Items

N

Cronbach’s α

Q.2.3.1, Q.2.3.2, Q.2.3.3, Q.2.3.4 261

0.867

Q.2.3.5, Q.2.3.6, Q.2.3.7, Q.2.3.8 261

0.394

Q.2.3.10*, Q.2.3.11*, Q.2.3.12*

261

0.825

Q.2.4.1, Q.2.4.2, Q.2.4.3

261

0.685

Responsibility

Q.2.5.1, Q.2.5.2, Q.2.5.3, Q.2.5.4 261

0.909

Attitude

Q.2.6.1, Q.2.6.2, Q.2.6.3, Q.2.6.4 261

0.838

IRQ

Q.2.11.1, Q.2.11.2, Q.2.11.3,
Q.2.11.4, Q.2.11.5, Q.2.11.6,
Q.2.11.7, Q.2.11.8, Q.2.11.9,
Q.2.11.10*, Q.2.11.11*

0.967

242

Mean (s.d.)
5.082
(0.669)
4.045
(1.228)
3.410
(0.210)
5.289
(0.224)
4.963
(0.277)
4.863
(0.682)
2.359
(0.195)

* Items recoded because of reverse coding

The reliability of the communication effectiveness measure was 0.685 and all inter-item
and item-total correlations were larger than 0.30. The four-item responsibility scale showed very
good reliability and all inter-item and item-total correlations were larger than 0.60. Similarly,
the attitude measure was found to be very reliable. The reliability of estimate of IRQ (shortened)
was calculated. Cronbach’s alpha of the scale was 0.967. None of the inter-item correlations
were less than 0.55 while all item-total correlations stood above 0.70. The scale appeared to be
reliable.
EXAMINATION OF PROPOSITIONS
As proposed in Chapter 3, the propositions were examined using ANCOVA. It can be
noted again that although referent power was originally proposed as a covariate, it was not
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included in the analysis because of inadequate reliability of the measure. Before proceeding with
ANCOVA analysis, an examination of the assumptions of ANCOVA was undertaken.
Assumptions of ANCOVA
While performing ANCOVA analysis it expected that covariates were correlated with the
DV such that they account for variance in the DV that is otherwise unexplained. To examine
such relationships, bivariate correlations were estimated (Table 12). All correlations between the
covariates and willingness to influence were significant (p<0.01) and appeared in the direction
conceptualized. All correlations except one among the covariates were also significant (p<0.01).
However, these correlations were, at best, moderate (Myers and Well, 2003). Thus, it can be
expected that multicollinearity should not be an issue.
Table 12: Correlations among Covariates and DV
Pow - dep
Pow -info
Com. effect Respon
Willingness to influ
0.417*
-0.139*
0.356*
0.320*
Pow - dep
-0.402*
0.313*
0.376*
Pow - info
-0.202*
-0.254*
Com. effect
0.213*
Respon
*Correlation is significant at the 0.01 level (2-tailed).

Attitude
0.179*
0.190*
-0.012
0.228*
0.225*

A critical assumption of ANCOVA is homogeneity of regression slopes among treatment
groups. This assumption was evaluated by performing ANOVA on the DV where significance
of all group by covariate interactions were examined. The group variable was a categorical
variable that represented four experimental groups. None of the interactions were significant at
the 0.05 level, thus, the relationships between the covariates and the DV appeared similar across
all treatment groups.

Concerning independence of covariates and IVs, treatment affecting
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covariate was not a concern because the covariates were measured before the experimental
manipulation was introduced.
There were only four extreme cases of scores on the DV considering all groups
individually. The distribution of the DV in each group was negatively skewed. Responses in the
specialist-high appropriate group showed the highest skewness, followed by that of the
specialist-low appropriate group. The distributions of the DV in each group showed departure
from normality (Shapiro-Wilk test p-value <0.05); however, departure from normality does not
have serious consequences on the results of ANCOVA as long as sample sizes are large and
equal and in the case of the current study, cell sizes vary very little (Myers and Well, 2003).
Results of ANCOVA Analysis
The ANCOVA results are presented in Table 13.

The results revealed that two

covariates, power of dependency and pharmacist’s perceived responsibility, were significantly
(p<0.05) related with a pharmacist’s willingness to influence off-label prescribing. However,
interpretation of main effects may not be appropriate in presence of significant interactions
(Meyers and Well, 2003).

Following this argument, the interactions were analyzed and

discussed first. The results shows that the interaction between power differential and IRQ is
significant (F(1, 230)=4.693; p=0.031). In other words, the effect of pharmacist’s perceived
relative expert power on willingness to influence prescribing is moderated by pharmacist’s
perceived negative impact on relationship quality with physician. This provides evidence in
support of Proposition 4 (the effect of pharmacist’s relative expert power on pharmacist’s
willingness to influence prescribing would be moderated by perceived appropriateness of offlabel prescription medication).

However, this result does not support Proposition 3 (F(1,

230)=3.489, p=0.063) at the a-priori significance level of 0.05. Interestingly, the interaction
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between IRQ and appropriateness emerged to be strongly significant (F(1, 230)=9.541, p=0.002).
The effect of perceived appropriateness on pharmacist’s willingness to influence is moderated by
perceived impact on relationship quality. It was proposed that perceived appropriateness of
prescription medication would be negatively associated with pharmacist’s willingness to
influence prescribing. The result revealed a significant (F(1, 230)=8.632, p=0.004) main effect
of appropriateness. Estimated marginal means (Table 14) of a pharmacist’s willingness to
influence in circumstances where the prescription is perceived less appropriate is greater than in
situations where the prescription is perceived more appropriate (off-label but with more
evidence). Thus, Proposition 2 was supported, although the interpretation of this main effect
deserves caution in presence of a significant interaction.
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Table 13: Tests of Between-Subjects Effects
Dependent Variable: Willingness to influence
df

Mean
Square

F

Sig.

151.579a

11

13.780

12.462

<0.001

Intercept

19.350

1

19.350

17.500

<0.001

Power differential

4.353

1

4.353

3.937

0.048

P1

Appropriateness

9.545

1

9.545

8.632

0.004

P2

IRQ

26.463

1

26.463

23.932 <0.001

Power dependency

20.974

1

20.974

18.968 <0.001

Power information

1.062

1

1.062

.960

0.328

Communication. Effectiveness

2.760

1

2.760

2.496

0.116

Attitude

.003

1

.003

.002

0.962

Responsibility

10.584

1

10.584

9.572

0.002

Power diff * Appropriateness

3.858

1

3.858

3.489

0.063

P3

Power diff *IRQ

5.189

1

5.189

4.693

0.031

P4

Appropriateness * IRQ

10.549

1

10.549

9.541

0.002

Error

254.322

230

1.106

Total

7930.200

242

Corrected Total

405.901

241

Source
Corrected Model

Type III Sum
of Squares

Proposition

a. R Squared = 0.373 (Adjusted R Squared = 0.343); b. Computed using alpha = 0.05
*Data excluded incompatible and flagged cases.

The effect of expert power differential between the pharmacist and the prescriber was
examined. It was proposed that pharmacist’s perceived relative expert power in relation to
physician would be positively associated with pharmacist’s willingness to influence off-label
prescribing.

Expert power differential did have a significant (F(1, 230)=3.937, p=0.048)

relationship with pharmacist’s willingness to influence. Surprisingly, direction of association
appeared different from what was proposed. The estimated marginal means for willingness to
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influence was lower for the low power differential (general physician) group as opposed to that
for the high power differential (specialist) group. Thus, although Proposition 1 was supported
partially, it should be cautiously interpreted as noted above.

Table 14: Estimated Marginal Means for Main Effects
Variable

Group

Mean

Std.
95% Confidence Interval
Error
Lower Bound
Upper Bound
a
0.099
5.381
5.772
Degree
of Experiment/low 5.577
a
appropriateness off-label/high
5.535
0.094
5.349
5.721
a
Expert power GP-low
5.550
0.098
5.357
5.742
a
differential
5.374
5.750
Specialist-high
5.562
0.096
a. Covariates appearing in the model are evaluated at the following values: power of
dependency = 5.0816, power of information = 3.4339, comm. effect = 5.2920, attitude =
4.8419, responsibility = 4.9607, IRQ = 2.3590. * N = 242.
The aforementioned results revealed significant interactions as well as main effects;
especially noteworthy was the interplay between three IVs. Differences in opinion exist as to
when one should look at simple effects. Following the recommendation of Myers and Well
(2003), simple effects that were determined to have theoretical interest and practical utility were
analyzed. In order to understand a complex set of effects that seem to be driven strongly by IRQ,
separate ANCOVA analyses were undertaken within the two levels of expert power differential
and the two levels of appropriateness. It should be noted here that all of these tests can be
considered conservative (less powered) because error mean squares are bigger than that of the
full model. As was mentioned previously (Table 13), it appeared that IRQ might play a strong
role in pharmacists’ willingness to influence.

To interpret the effect better, IRQ was

dichotomized on the median value of two so that interactions involving IRQ can be plotted.
Figures 1 and Figures 2 describe interaction plots that involve IRQ. These interactions showed
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what Kleinbaum et al. (2008) called the same direction effect and both were significant at the
0.05 level. Although insignificant (p=0.063), the interaction (Figure 3) between power and
appropriateness showed reverse direction (Kleinbaum et al., 2008). Within the specialist group,
the main effects of appropriateness (p=0.045) and IRQ (p<0.001) as well as interaction were
significant (p=0.004). However, within the generalist group neither the interaction (p=0.171)
between appropriateness and IRQ nor the main effects of appropriateness (p=0.056) and IRQ
(p=0.118) were significant. When the simple effects within different appropriateness levels were
analyzed, none of the main effects or interaction between expert power differential and IRQ were
significant at p=0.05 level in the high appropriate group. In contrast, within the low appropriate
group, the interaction between IRQ and power differential was significant (p=0.029). While the
main effect of power differential was not significant (p=0.144), that of IRQ was significant
(p=0.029).

It should be noted here that none of the simple comparisons with Bonferroni

adjustments under these within-group analyses were significant at the 0.05 level.
Overall, the model was significant and 34.3% variance (adjusted) was explained by the
model. The variables of interest contributed substantially to the total explained variance in the
model. Among the effects, IRQ stood above any other variables in terms of its ability to explain
variability of willingness to influence.
Post-hoc Analyses to Examine the Sensitivity of the Results
Initially, it was planned that population would consist of pharmacists solely from
nonacademic community hospitals. However, in the interest of pragmatism, data collection
included pharmacists employed by academic medical centers (AMCs). ANCOVA analysis was
performed to determine if there is any difference in effects based on type of hospital (AMC vs.
non-AMC). A main effect term of dichotomous hospital type and three interactions with power
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differential, appropriateness, and IRQ were added to the full model that was used to examine the
propositions. Neither the addition of new terms changed the pattern of results nor were any of
them significant. Indeed, the result from the new model with all interaction terms replicated the
original findings.

Thus, hospital type (AMC vs. non-AMC) does not appear to affect

pharmacist’s willingness to influence off-label prescribing. It was expected that nonacademic
hospitals would be less likely to have an IRB, which may influence the manner in which offlabel prescribing is handled within the hospital (Ansani et al., 2006). However, because only a
small percentage (<20%) of hospitals reported not having an IRB, statistical analysis may not
show reliable estimates. Instead, the effect of existence of policy regarding off-label prescribing
in their hospital was examined by adding to the original model a new main effect term for policy
and its interaction terms with three variables (power, appropriateness, and IRQ). Of all subjects
who were included in the ANCOVA model, 98 respondents reported that their hospital had a
policy that addressed off-label medication use.

The results did not change the pattern of

significant effects except that, unlike the case of hospital type, power differential and
appropriateness interaction became marginally significant (p<0.10). It may be argued that the
results from this analysis are expected and may appear redundant given that groups were similar
with respect these variables. However, because our measures are not free from measurement
error, the objective was to rule out any potential threat that may be associated with these
variables. Do perceptions about key variables differ in different types of institution? It was
observed that while hospital type did not affect the way expert power differential,
appropriateness, or IRQ were perceived, the presence of an off-label medication use policy
seems to have marginal effects – main effect of policy on power (p=0.097) and interaction of
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appropriateness group and policy on appropriateness (p=0.055) – on how appropriateness and
relative expert power are perceived.
The impact of inclusion of pharmacists who reported to spend 10% of their time or less
on clinical duties also was investigated. The study obtained responses from 51 pharmacists who
reported to spend currently 10% or more of their weekly working hours on clinical duties.
Percentage of time spent on clinical duties and its interaction with appropriateness, power
differential, and IRQ were added to the original ANCOVA model and the analysis was run
again. No changes in significant effects were observed in the new model as compared to the
main model except that time on clinical duties and its interaction with relational impact were
marginally significant (p<0.1). Interestingly, while significance of previously found effects were
retained, the main effect of power differential also became marginally significant (p=0.052) once
newly added interaction terms were dropped. However, when people with less than 10% time on
clinical duties were excluded and the model was run, main effects of appropriateness and IRQ
and their interaction remained significant (p<0.05) and so did covariates as in the original model.
The loss of significance of the interaction effect between power and IRQ, which was otherwise
significant, was further investigated. As reported before, group composition was not different
based on time spent on clinical duties. Similarly, the number of respondent pharmacists reported
to devote less than 10% and 10% or more of time on clinical service in each experimental group
were not different (χ2= 0.578, df=3; p=0.90). ANOVA analyses were performed to examine if
they had different perception of expert power differential, appropriateness, and relational impact.
These two groups of pharmacist respondents did not differ in any of the three perceptions
mentioned above as revealed by insignificant (p<0.05) interactions and the main effects of the
dichotomous variable -time spent on clinical duty. Thus, it is possible that the failure to observe
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significant power-IRQ interaction in pharmacists who devote 10% or more time may have been
caused by loss of power.
During the conceptualization phase of this project, concerns were raised that responses by
pharmacists regarding willingness to influence may be subject to social desirability bias. It was
suggested that including a related, but different, construct (i.e., intention to act) might provide a
validity check of the results. Items measuring likelihood to act (intention) immediately followed
the measure of the DV in the survey questionnaire. Likelihood to act showed high and positive
correlation (p<0.05) with the DV. ANCOVA analysis on likelihood to act did not replicate the
results but showed similar trends. While the interaction of IRQ with power differential and
appropriateness remained marginally significant (p<0.10), the main effect of power differential
was no longer significant (p=0.34). However, IRQ and appropriateness remained significant
(p<0.05). Interestingly, the pattern of observed cell means (Table 15) makes strong sense.
Although likelihood of intention was a different, but related, construct, such trends of similarities
in results may increase our confidence in the findings of the study.

Table 15: Observed Cell Means of Likelihood to Act
Expert power
differential

Degree of
appropriateness

Mean

Std.
Deviation

N

GP-low

Experiment/low

5.728

1.306

59

Off-label/high

4.611

1.611

60

Experiment/low

5.246

1.617

57

Off-label/high

4.404

1.938

66

Specialist-high
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Effect of Interaction between IRQ and Expert Differential on
Willingness to Influence

104

Effect of Interaction between IRQ and Perceived Appropriateness
on Willingness to Influence
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Effect of Interaction between Perceived Appropriateness and
Expert Differential on Willingness to Influence

106

CHAPTER 4 REFERENCES
Ansani N, Branch R, Fedutes-Henderson B, et al. Unites States medical practice summary
Innovative off-label medication use. American Journal of Medical Quality. 2006;21:246-54.
Black B, Babin B, et al. Multivariate Data Analysis, 6th ed., [Hardcover], Upper Saddle River,
NJ: Prentice Hall; 2006.
Census Bureau Regions and Divisions with State FIPS Codes.US Census
Bureau.http://www.census.gov/geo/www/us_regdiv.pdf. Accessed 9 July, 2010.
Churchill GA., Surprenant C. An investigation into the determinants of customer satisfaction. Journal of marketing Research. 1982;19:491-04.
Churchill Jr. GA. A paradigm for developing better measures of marketing constructs,” Journal
of Marketing Research. 1979;16:64-73.
Gerbing DW, Anderson JC. An updated paradigm for scale development incorporating
unidimensionality and its assessment. Journal of Marketing Research. 1988;25:186-92.
Hair Jr. JF, Black WC, Babin BJ, et al. Multivariate data analysis. 6th ed. Upper Saddle River,
NJ: Prentice Hall; 2006.
Kleinbaum DG, Kuppe, LL, Muller.KE. Applied Regression Analysis and Other Multivariable
Methods, 4th ed., Belmont, CA: Duxbury Press; 2008.
Knapp KK, Blalock SJ, Black BL. ASHP survey of ambulatory care responsibilities of
pharmacists in managed care and integrated health systems – 2001. American Journal of
Health System Pharmacists. 2001;58:2151-66.
Miller GM, Chapman JP. Misunderstanding analysis of covariance. Journal of Abnormal
Psychology. 2001,110:40-8.
Myers JL, Well A. Research Design and Statistical Analysis, 2nd ed., Mahwah, NJ: Lawrence
Erlbaum Associates Publishers; 2003.
Peter JP. Reliability: A review of psychometric basics and recent marketing practices. Journal of
Marketing Research. 1979;16:6-17.
Raven BH, Schwarzwald J, Koslowsky M. Conceptualizing and measuring a power/interaction
model of interpersonal influence. Journal of Applied Social Psychology. 1998;28:307-32.
Schriesheim CA, Hinkin TR. Influence tactics used by subordinates: A theoretical and empirical
analysis and refinement of the Kipnis, Schmidt, and Wilkinson subscales. Journal of Applied
Psychology. 1990;75:246-57.
Singleton RA, Straits BC. Approaches to Social Research, 4th ed., New York, NY: Oxford
University Press; 2005.

107

CHAPTER 5
INTERPRETATION AND CONCLUSION
Off-label prescribing has drawn a lot of attention from different interested parties both
within healthcare and in society. A substantial extent of effort has been driven into examining
the prevalence, defined broadly, of off-label prescribing in current medical practice (Cuzzolin,
Zaccaron, and Fanos, 2003; Radley, Finkelstein, and Stafford, 2006). Additionally, the known
literature focuses, to a relatively lesser extent, on explanations as to why such behavior exists in
the first place. For example, some studies attempted to understand why physicians prescribe
medications off-label and elucidate the factors that were associated with such practice (EkinsDaukes et al., 2005; Lin, Phan, and Lin, 2006). Although not appropriate in all cases, much of
current opinion stands in favor of prescribing medicines off-label; however, judicious use is
expected. In other words, using the privilege where it is needed and justified has the potential
greatly to benefit patients. Thus, attention should be paid to improve the quality of off-label
prescribing emphasizing an extended and extensive judgment of appropriateness. Although
physicians have been surveyed sporadically to understand off-label medication use, pharmacists
were neglected largely in the literature. Thus, the present study was undertaken to explore if
quality initiatives could be strengthened by pharmacists who are recognized as experts in
pharmacotherapy.

Specifically, the study focused on whether pharmacists were willing to

influence the off-label prescribing behaviors of physicians. Like other studies that examined
interpersonal relationships in healthcare (Fung, 1991; Raven, 1992), social power, a
psychological construct, was one of the focal variables in the study. Perceived expert power
difference, perceived appropriateness of the off-label prescription, and perceived negative impact
on relationship quality between the pharmacist and the prescriber following an attempt to
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influence were independent variables that examined pharmacist willingness to influence off-label
prescribing. Using an experimental design, this survey examined the following propositions:
P1:

The pharmacist’s perceived relative expert power in relation to the physician is
positively associated with the pharmacist’s willingness to influence off-label
prescribing.

P2:

The perceived appropriateness of prescription medication is negatively
associated with the pharmacist’s willingness to influence off-label prescribing.

P3:

The effect of the pharmacist’s relative expert power on the pharmacist’s
willingness to influence off-label prescribing is moderated by the perceived
appropriateness of prescription medication.

P4

The effect of the pharmacist’s perceived relative expert power on willingness
to influence off-label prescribing is moderated by the perceived impact on
relationship quality with the physician as perceived by the pharmacist.

Perceived Relative Expert Power
In the present study, vignettes were used to manipulate the perceived expert power
differential between the prescribing physician and the pharmacist respondent.

Pharmacists

assigned to the specialist group rated the physician as having more expert power (high power
differential) than did those pharmacists assigned to the generalist group.

As a result, the

manipulation of power was determined to be effective. The results from the present study are
summarized in Table 16 and showed that pharmacist’s perceived relative expert power in
relation to physician was associated with pharmacist’s willingness to influence off-label
prescribing. However, contrary to what was expected, willingness to influence was higher when
power differential increases (Table 14).

This finding is unexpected; however, it may be

explained possibly by uncertainty reduction theory (Berger and Calabrese, 1975). Uncertainty
reduction theory proposes that increases in information seeking behavior may be observed to
reduce uncertainty. The study limited the pharmacist’s evaluation of the physician’s superiority
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in knowledge to the descriptions in the vignettes. Such uncertainty may be reflected in the
evaluation of specialists as revealed by the mean rating of power differential of specialist group
that stands very close to 4 or midpoint, which means not sure or no opinion, of the scale (Table
8). As a result, uncertainty in the pharmacist’s mind may have expressed itself as willingness to
influence when it may have actually been an action to seek clarification about the rationale
regarding the prescription. In the light of this finding, several points should be mentioned. First,
the effect size of power differential may be small as opposed to medium (assumed during sample
size calculation prior to the execution of the study). This point may be substantiated by the fact
that, although statistically different, the difference in expert power differential as perceived by
pharmacists in the two groups was, practically speaking, very narrow. In general, pharmacists
slightly disagreed that the physician described in the scenario had more expert power than
pharmacists as indicated by the mean scores that lay between 3 and 4 on a 7-point scale (Table
8). If the true effect size is small, increasing sample size may reveal this effect, if it exists, more
strongly. Secondly, the independent effect of power differential may not either exist such that it
influences pharmacist’s decisions about professional judgment or it may not have any practically
meaningful effect. Within the context of pharmacist-physician communication, past research
found that power differential was not a significant predictor of pharmacist’s communication
behavior (Lambert, 1996).

Presently, pharmacy education in the US emphasizes heavily

pharmacotherapeutics through its didactic curriculum and clinical clerkships (ACPE, 2006).
Thus, pharmacists educated in this manner may not perceive physicians superior concerning
expertise in medication-related matters. Moreover, information about the residency training of
the respondents was not collected during the project. It is possible that professional socialization
occurred differently for pharmacists who completed residencies and may have affected the
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manner in which pharmacists perceived their interaction with physicians. Lastly, the responses
may suffer from social desirability bias that may be operating in different directions in different
experimental groups related to power. This possibility is supported by the pattern of mean
responses, as explained below, on the power manipulation. In general, pharmacists may perceive
physicians slightly superior in expert power but not so much that the gap in perceived power
differential is large depending on physician specialty. In other words, in the generalist group
there may be floor effect such that physicians have to be rated more powerful, whereas in the
specialist group there may be both floor and ceiling effect. This effect may be accentuated by
the characteristic, i.e., high clinical acumen, of the respondents. Moreover, the standard error of
the mean scores in the power manipulation (Table 8) was larger in the specialist group even
though the number of subjects was greater. A relatively less precise estimate in the specialist
group may attest to the existence of such an effect. As such, the potential bias may have affected
responses to the DV. For example, within the high appropriate group, willingness to influence
was second highest among all – conceptually predicted to be the lowest – in the specialist group
as compared to the generalist group (Table 14). Although some potential explanations are
offered below, this pattern of response remains to be understood clearly.

Finally, power

differential may not have any independent effect but may act in a complex manner as reflected
by the interaction of perceived power differential with IRQ. At this point, it can be noted that the
independent effect of power did not appear in some of the post hoc analyses (Table 16). Thus.
the main effect of power differential should not be emphasized or, at best, it should be
interpreted cautiously.
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Table 16: Summary of Results
Analysis Model

Results

Full ANCOVA model

Main Analysis

ANCOVA within Specialist
ANCOVA within Generalist1
ANCOVA within high
Appropriateness
ANCOVA within low
Appropriateness
ANCOVA: AMC vs. NonAMC included
ANCOVA: with Policy vs.
No-policy2 included

Post-hoc analysis

ANCOVA: Clinical service
(<10% vs. ≥10%) included

Power, Appropriateness, IRQ,
Power*Appropriateness^,
Power*IRQ,
Appropriateness*IRQ
Appropriateness, IRQ,
Appropriateness*IRQ
Appropriateness^

Power, Power*IRQ
Power, Appropriateness, IRQ,
Power*IRQ,
Appropriateness*IRQ;
Power, Appropriateness, IRQ,
Power*Appropriateness^,
Power*IRQ,
Appropriateness*IRQ
Power, Appropriateness, IRQ,
Power*Appropriateness^,
Power*IRQ,
Appropriateness*IRQ
Duty^, Duty*IRQ^

ANCOVA excluding
pharmacists with Clinical
service <10%

Appropriateness, IRQ,
Appropriateness*IRQ

ANCOVA: Likelihood to act
as dependent variable

Appropriateness, IRQ,
Appropriateness*IRQ^,
Power*Appropriateness^

Terms that appear are significant at p<0.05 level.
^ p<0.10
1
p >0.05 for all variables of interest;
2
Two-way ANOVA analyses showed policy had marginal (p=0.097) effect on power perception
and the interaction of appropriateness and policy on appropriateness perception (p=0.055).
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Perceived Appropriateness of Off-label Medication
The appropriateness of off-label prescribing, not the practice itself, is debated most
heavily and has raised concerns among different stakeholders (AHRQ, 2007). Knowing this, the
judgment of appropriateness is critical and as long as appropriateness is evaluated carefully, offlabel prescribing has the potential to provide positive outcomes not achievable with current
therapies. Although “appropriateness” may be debated, or driven by case-specific variables, this
study relied on ratings on different aspects of appropriateness as recommended by a standard
drug monograph. During the instrument development and pretest, general opinions about the
appropriateness of the medication demonstrated that the two examples of off-label prescriptions
were, in fact, different on this variable. The manipulation check further confirmed that the two
medications were indeed considered different, as hypothesized, in terms of appropriateness.
Unlike the power manipulation, the difference in appropriateness as perceived by pharmacists in
the respective groups was large and ratings lay on two sides of the mid-point of the scale (Table
8). The between-subject ANCOVA results confirm that perceived appropriateness of medication
is negatively associated with pharmacist’s willingness to influence off-label prescribing. In other
words, if a pharmacist has evidence that does not support an off-label use he or she will be more
willing to influence the prescriber’s judgment. This result makes sense and is consistent with the
pharmacy literature.

Past studies confirm that pharmacists intervene in order to improve

prescribing and to change prescribing practices that are considered inappropriate (Rupp,
DeYoung, Schondelmeyer, 1992; Hanlon et al., 1996). Moreover, institutional practices in many
US hospitals are governed by protocols or policies; practices that deviate from this norm may
make the pharmacist less concerned about questioning the judgment of physician. In the present
study, pharmacists in both appropriateness groups demonstrated a willingness to influence;
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however, those in the low appropriateness group reported a higher willingness to influence the
prescriber. A potential explanation for pharmacist’s higher willingness to intervene in the case
of evidence-based off-label medicine may be because they may opine that any medication order
that is not on-label necessitates additional judgment. The present study does not permit us to
draw such a conclusion; however; performing a role that brings about expert evaluation by
pharmacists would, at the very least, assure society about safe and effective prescribing and
medication use.

Another potential reason may be the effects of other variables and their

interactions (three-way type of influence). In this context, it should be mentioned that the main
effect of a variable cannot summarize its effect in the presence complex interactions. Thus, it is
emphasized here that the main effect of appropriateness is not sufficient and not appropriate to
understand its effect on willingness to influence as revealed in the study.
Table 17: Estimated Marginal Means of Power-Appropriateness Interaction (N=242)
Dependent Variable: willingness to influence
Degree of
appropriateness
Experiment/low
Off-label/high

Expert power
differential

N

Mean

95% Confidence Interval
Std.
Error Lower Bound Upper Bound

GP-low

59

5.696

0.140

5.420

5.973

Specialist-high

57

5.453

0.140

5.177

5.729

GP-low

60

5.399

0.138

5.127

5.672

Specialist-high

66

5.673

0.131

5.414

5.932

Although the study’s third proposition (the effect of pharmacist’s relative expert power
on pharmacist’s willingness to influence off-label prescribing is moderated by perceived
appropriateness) was not supported, the interaction between appropriateness and IRQ, was
significant. Proposition 3 was not supported possibly because of some of the limitations or
reasons discussed in the previous discussion on social power. Specifically noteworthy is that the
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study may lack power to detect such effect. It can also be noted here that the plot (Figure 3) of
the interaction between power and appropriateness, although not significant (p=0.063), presents
an interesting reverse direction effect. Although it cannot be concluded, it is possible that low
appropriate conditions create an uncertainty, as may be implied by higher standard error in the
low appropriate condition (Table 17). When a highly expert consultant physician writes an offlabel prescription that appears to be lacking in evidence for its use, because of uncertainty, the
evaluating pharmacist might attribute the lack of evidence to either lack of information possessed
by the pharmacist or to the physician’s special expertise and skill that are critical to utilizing such
information. Under such uncertainty, pharmacists may rely on a limited number of heuristics
(Kahneman and Tversky, 1973) such as specialty and experience of the physician and as a result
overestimate the physician’s power such that it reduces their relative ability to perceive risk.
Now one may argue that it should not happen as information power was not significant.
However, rather than experimentally controlling for information power, it was measured. In
addition, information may be meaningful but meaning is not inherent in information; it requires
interpretation (Johnson, 1993). Due to lack of interpretation of information or uncertainty, the
pharmacist may perceive the physician to be more expert than the physician actually is and thus
reduce his or her willingness to influence. Alternatively, fibromyalgia, a disease state that is
debated (Berenson, 2008), might have prompted pharmacists’ willingness to report that they
would intervene when the objective of the interaction was to secure knowledge from the
specialist.
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Impact on Relationship Quality (IRQ)
In the framework of the power/interaction model of interpersonal influence, Raven
(1992) postulated that influence attempts might result in negative outcomes in interpersonal
relationships. The social psychology literature is replete with studies that show such outcomes
(Yukl and Tracey, 1992) exist. In the context of the pharmacist-physician relationship, concerns
such as those mentioned are not unfounded. As a result, effort was made to measure the
pharmacist-physician collaborative relationship (Zillich et al., 2004; Doucette, Nevins,
McDonough, 2005).

Unlike the other two independent variables, IRQ was measured with

multiple items that were taken from multiple studies (Morgan and Hunt, 1994; Roberts, Varki,
and Brodie, 2003; Dobson et al., 2006) such that it examined all relevant negative outcomes.
However, in contrast to the conceptualization, IRQ emerged as a two-factor construct. It should
be mentioned that the relationship quality scale proposed by Dobson et al., (2006) also had two
factors (relationship with physician and profession prepared to participate). However, in order to
be consistent with the study’s conceptualization and in the interest of model parsimony a single
factor IRQ that explained a substantial part of total variance was used in subsequent analysis.
Pharmacists, in general, did not perceive a substantial negative impact on their interpersonal
relationship with the prescriber in the event that they made an attempt to influence (mean=2.36,
s.d.=1.24 using a 7-point scale (1=not at all, 7=absolutely)).

IRQ was measured after

manipulations were introduced. However, manipulated variables did not appear to affect (p>0.1)
the manner in which pharmacists responded to the IRQ measure.
After controlling for covariates, perceived expert power differential between the
physician and pharmacist affects pharmacist’s willingness to influence differentially in different
power groups with changes in IRQ as perceived by the evaluating pharmacist (Figure 1). Thus,
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in situations where the pharmacist perceives a high power difference, the pharmacist’s
willingness to influence off-label prescribing reduces more sharply with an increase in perceived
IRQ as compared to willingness to influence in the low power difference condition. In other
words, when there is an increase in pharmacist’s relative power (as in the generalist group) IRQ
has a weaker effect on the pharmacist’s willingness to influence off-label prescribing. This
statement is further supported by the findings in the post-hoc analyses. In the generalist group,
only appropriateness significantly affected the pharmacist’s willingness to influence (Table 16).
This is an interesting finding and is consistent with what Raven (1992) suggested. It can be
noted here, that power is not a zero sum game and in order to be effective, professional groups
may exercise power over decisions within their sphere of competence (Flood and Scott, 1978).
Although perceived power differential has been conceptualized as a physician’s power it can be
applied to a pharmacist’s power thus making the role of power differential more generalizable.
While the study did not hypothesize a priori the interaction between appropriateness and
IRQ, post-hoc analysis supported the moderating effect of IRQ being more pronounced in the
low appropriateness group than in the high appropriateness group (Figure 2). When pharmacists
are less concerned about relational outcomes, decreases in appropriateness of therapy appear to
increase the pharmacist’s willingness to influence. What this implies is that appropriateness (or
lack thereof) of a prescription creates a logical ground for the pharmacist to make an influence
attempt on a physician; however, it may not be very straightforward if pharmacists are concerned
about the outcomes of those influence attempts.
Indeed, like any other professional relationship, IRQ seems to have a consistent and
pronounced influence in pharmacists’ decision-making. This is consistent with the pharmacy
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literature where concerns about fostering good relationships with physicians are echoed (Comer
et al., 2009).
The results of the study appear to be robust. Under different assumptions as examined in
several post-hoc analyses, the effect of variables of primary interest did not change. A striking
difference in the results was observed when the post-hoc analysis included pharmacists spending
10% or more of their working hours on clinical pharmacy services or direct patient care services.
Even in this condition, the same effects as in the original model were observed with the
exception of those related to power differential. One reason for such a result may be a lack of
power. Expert power appears to have a subtle effect. As a result, when clinical duty is added as
continuous variable in the model some effects involving expert power reappeared. Another
reason for such result may be that the effect of expert power is subsumed in responsibility and
power of dependence both of which appear significant consistently as these are groups that may
perceive such duties as part of their normal routine. For some, it may be disturbing that the
concern over the impact on relationships overrides or dictates over evidence-based
appropriateness judgments with regard to pharmacist’s willingness to influence. However, such
findings represent realism. More assuring was the pharmacists’ willingness to influence offlabel prescribing, in general. Although concerns about relational consequences and attempt to
influence relationship exists, increasing pharmacist’s expert power or another social power (i.e.,
decreasing power differential) may alleviate some of this concern. Although this study did not
provide evidence to conclude as such, it is also possible that in the present practice framework,
pharmacists are not interacting with physicians on this issue on a regular basis. Thus, concerns
about relationships may be overstated.

118

LIMITATIONS OF THE STUDY
This study has limitations that may affect generalizability and should be kept in mind
while interpreting its results. Important limitations and a discussion of their potential impact on
the findings of the present study follow.
Manipulation of variables
One of the assumptions of ANCOVA is that independent variables (IV) do not affect
each other.

Manipulation checks reveal that power differential may have affected the

appropriateness ratings by the respondents. This means that the medications appeared more
appropriate if it was prescribed by a specialist rather than a generalist (Table 18). In the real
world, expert power and appropriateness judgments are combined inextricably and thus there
was a degree of realism in this study. Order bias may be present in the study because the power
manipulation check was introduced before the appropriateness manipulation check in all
instances, thus creating an anchoring effect (Landon, 1971) and as such, this effect appeared only
in the manipulation rating. Although manipulation checks that are rated much later do not
convincingly state that IVs affect each other that were fixed by the design in the present study,
the results should be cautiously interpreted. Under the circumstance of non-independent or
falsified manipulation, misleading results may be possible (Perdue and Summers, 1986).
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Table 18: Tests of Between-Subjects Effects on Independence of Independent Variables
Dependent Variable: appropriateness
Type III Sum of
Squares

Source
Corrected Model

216.52a

df

Mean Square

F

Sig.

3

72.17

53.57

<0.001

Intercept

5073.42

1

5073.42

3765.47

<0.001

Power dif

19.81

1

19.81

14.71

<0.001

Appropriateness

193.91

1

193.91

143.92

<0.001

0.01

1

0.014

0.01

0.919

Error

346.27

257

1.35

Total

5674.00

261

Corrected Total

562.79

260

Power dif * Appropriateness

a

. R Squared = 0.385 (Adjusted R Squared = 0.378)

Vignette design
The study designed four vignettes that came from crossing two manipulated variables.
Vignettes have been used in past research in clinical settings including studies examining quality
of clinical practice (Epstein et al., 2001; Peabody et al., 2004). However, the vignettes had some
limitations in terms of providing adequate information (e.g., treatment history) that may be
required for evaluation by pharmacists. In other words, the vignette might lack realism and may
suffer because of lack of essential information. It is also possible that vignette had a cuing effect
for the appropriateness measure and demand characteristics for the DV. Responses to vignettes
with cueing items are believed to lead to overestimation of performance (Sandvik, 1995) and
may have inflated the pharmacists’ willingness to influence off-label prescribing.

How a

pharmacist assesses appropriateness in a real-life off-label prescribing situation may not be
reflected accurately using a vignette-based research design.
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Coverage error
The study sample was not drawn randomly using any probability sampling technique.
Data collection for this study occurred online through an email invitation sent out by the
participating state affiliates of the ASHP. As such, some pharmacists may not hold membership
with the respective state affiliate. Additionally, it is possible that pharmacist members may not
have email access.
Response rate and related issues
Generally, it is considered good practice, if not mandatory, in survey research to report
response rate, which provides primary evidence about generalizability of the results. In addition,
nonresponse bias may be examined by using different methods for the purpose of
generalizability (Singleton and Straits, 2005).

This study adopted a facilitated distribution

approach via email. As a result, it was not possible to estimate the number of pharmacists who
received the request to participate in the study and to determine when they received it; it was not
possible to calculate response rate and evaluate potential nonresponse bias, as is suggested
(Armstrong and Overton, 1977). Attrition rate during this study was high. Many of potential
respondents (approximately 40%) left very early after starting the survey. This group of people
may have different opinions on the issue than those responded. The design of the present study
does not allow us to analyze this group of potential participants because the respondent
terminated the survey before they were exposed to the experimental treatment. Thus, it can be
argued that attrition rate did not occur because of treatment, a noted threat to internal validity.
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Issues related to measures
In this study, measures were adapted from past studies that were not always related to
health care.

Although the measures used were all multi-item measures and the reliability

estimates of the scales were good or acceptable, caution should be exercised while interpreting
the results for several reasons. First, these scales are not well validated within the context of
health care.

Second, some measures did not behave according to conceptualization.

For

example, factor loadings of items of referent power were ambiguous and the scale’s reliability
was poor. Referent power may produce a halo effect or sleeper effect (French and Raven, 1965)
and is related to expert power. The effects of referent power could not be adjusted, which may
or may not bias the result. The information power scale emerged as a two factor solution as
opposed to theory that suggested that it was unidimensional. The IRQ measure also exhibited
this characteristic. As a result, the information power scale that was used in the analysis may not
adequately capture what it purported to do. While conducting post-hoc analysis using the
likelihood to act scale it was observed that information power became significant. It was not
clear if that result occurred because of measurement inadequacy. One of the assumptions of
ANCOVA is that covariates are measured without error. This assumption may not be tenable,
especially in the light of the fact that our measures may have issues as described previously.
Although expert power or appropriateness was not used in the analysis such concerns may apply
to the measures that were included in the analyses as well. Measurement errors may have
serious consequences on the conclusions of survey studies (Hair et al., 2006). Although the post
hoc analyses provided some confidence, estimates may not be very robust unless advanced
techniques such as structural equation modeling are used to account for measurement errors.
Finally, the disease state fibromyalgia might have driven the response patterns. For example, the
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existence of fibromyalgia is debated (Berenson, 2008) and if respondents believed it as such it
might have affected their response.
Future Research Opportunities
The dependent variable in the present study was willingness to influence. Responses to
willingness to influence, on average, were on the higher side of the scale (all cell means above
5.5) and cell means were very close. It could be such that pharmacists are by nature willing to
influence regardless of whether the prescription is off-label or on-label. Alternatively, the word
“off-label” may have sensitized respondents and thus created demand characteristics. Future
research should explore pharmacist’s willingness to influence off-label prescribing in
comparison to on-label prescribing. Another potential reason for such high scores may stem
from social desirability bias. Although suggested techniques (e.g., assurance of anonymity,
highlighting the importance of the topic in cover letter, etc.) (Singleton and Straits, 2005) had
been applied to control such bias, it may be still an issue. Specifically, impression management,
which is associated with the desire to present oneself in a socially desirable manner (Paulhus,
1991) may be driving the response patterns observed. Respondents may be motivated to bias
their self-reported responses to the extent that the value is strongly prescribed or expected within
the social context or norms and has social meaning (King and Bruner, 2000). Future research
should disentangle the effect of such bias, if any.
Although pharmacists may be willing to influence, do they actually influence – moot
point of substantive concerns – when confronted with off-label prescribing situations that require
additional evaluation? In this study, the cell means of likelihood of influence were lesser then
their respective average values for willingness to influence. The models examining willingness
to influence and likelihood to act showed little difference with the most striking being the
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significance of information power in the latter, although differentiation between these constructs
exist (Armitage and Conner, 2001). The intention-behavior literature suggests that intention
does not correspond to behavior always (Sniehotta, Scholz, and Schwarzer, 2005; Sheeran,
2002).

Another interesting question that can and should be explored is what mode of

communication strategies pharmacists adopt when making their influence attempts. Pharmacistphysician communication is understudied relatively when compared to patient-physician or
patient-pharmacist communication. Thus, it would be interesting and enlightening to examine
pharmacist-physician communication with regard to influencing off-label prescribing, especially
in those low appropriate conditions where a degree of uncertainty exists.
It should be noted here that in all of the aforementioned analyses, appropriateness was a
fixed effect variable; however, it can also be considered a random effect variable with the
assumption that two scale points as represented by two groups were randomly chosen on a
continuum of appropriateness scale. Alternatively stated, can the study results be replicated in
situations that compose the universe of degrees of appropriateness?
The manipulation check on the power measure raises an interesting point. The large
standard error seen in the specialist group reflects variability of the scores and attests to
imprecision of the estimate and implies that our tests may have little power (Meyer and Well,
2003). In fact, this study was not powered to detect all effects in the model, including power and
appropriateness interaction. Future studies should be appropriately powered to examine the
effect before such effect is ruled out with confidence. This is important especially due to the
contaminating effect of manipulation.
Finally, the selected disease condition in the vignette did not have imminent life
threatening potential. The existing literature on off-label prescribing is replete with evidence that
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off-label prescribing occurs largely in life threatening diseases (Brosgart et al., 1996; Poole and
Dooley, 2004).

Pharmacists’ intent and perceived responsibility in those cases may be

interesting to study.

It may be worth studying especially, in the light of the fact that

responsibility was a strong and consistent predictor of willingness to influence. In addition,
future research may also revisit the results of the study in other disease conditions.
CONCLUSION
This study examined pharmacist’s willingness to influence off-label prescribing.
Willingness to influence represents a pharmacist’s willingness to ensure the rationality of offlabel prescribing. Experimental manipulations were used to examine the effect of perceived
relative expert power and perceived appropriateness on willingness to influence. Perceived
negative impact on interprofessional relationship quality was measured to investigate its
moderating effect on a pharmacist’s willingness to influence.

The effects of power of

dependence, informational power, communication effectiveness, attitude, and responsibility were
statistically controlled. The variables were measured using multi-item measures that showed
acceptable or satisfactory reliabilities.

Physician’s expert power relative to pharmacist or

perceived power differential between the pharmacist and physician affects pharmacist’s
willingness to influence off-label prescribing.

Perceived appropriateness of off-label

prescription medication negatively affects pharmacist willingness to influence as one would
expect. However, the effect of perceived power differential on willingness to influence does not
appear to depend on perceived appropriateness. In addition, significant moderating influences of
perceived impact on relationship quality were observed. With an increasing perception of impact
on relationship quality, perceived expert power differential more negatively affects pharmacist’s
willingness to influence. Thus, it indicates pharmacists are less willing to influence when
125

perceived power differential increases (e.g., specialist physician vs. general physician) if such an
attempt is speculated to bring about higher negative impact on the interprofessional relationship.
Similarly, combined effect of appropriateness and impact on relationship quality was observed.
With anticipation of increasing adverse relational outcomes, pharmacist’s willingness to
influence off-label prescribing decreases more in the low appropriate condition than in the high
appropriate condition. That is, pharmacists are less willing to influence off-label prescribing that
is perceived low as compared to high in appropriateness under an anticipated condition of
adverse relational consequences. Reverse phenomenon occurs when low negative outcomes
anticipated. Interestingly, perceived negative impact on relationship quality has an independent
effect on pharmacist’s willingness to influence. This study has basic requirements (random
assignment, manipulation of IV, measurement of DV) of a true experiment that ensure the
internal validity of the results (Singleton and Straits, 2005). In addition, the study had
participants from across the US including pharmacists from a mix of large and small states,
academic and nonacademic hospitals, private and public hospitals and pharmacists having
different job titles or responsibilities. Thus, such heterogeneity of respondents also ensures
generalizability of the results of the study. In summary, the findings show that pharmacists are
willing to ensure rationale behind off-label prescribing by intervening in off-label prescribing
situations. This should comfort the patient community and justify the pharmacist’s role and
strengthen their image as a provider of evidence-based healthcare solutions.
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APPENDIX A
Experimental Vignette

Dr. Smith is a general practitioner [rheumatologist] and joined your hospital two years ago.
[Dr. Smith is a highly recognized expert in the field of rheumatology. Dr. Smith is
considered an extremely knowledgeable physician with extensive clinical experience in
rheumatology.] Dr. Smith has 5 [20] years of experience of clinical practice. Previously, Dr.
Smith has [successfully] treated a few [many] patients with various medications prescribed
for off-label indications.

Dr. Smith has written an order for fluoxetine for the treatment of diabetic neuropathy
[fibromyalgia] for Jody Jones, 35, who was admitted to your hospital 1 day ago for a minor
injury. Fluoxetine treatment has been ordered using 20 milligrams/day for seven days and
then will be titrated until 40 milligrams/day is reached in two weeks in an out-patient
setting.

Existing [peer-reviewed] reports on efficacy of fluoxetine in diabetic neuropathy
[fibromyalgia] are inconsistent and inconclusive [favorable]. This information is based on
data derived from disjointed personal experience, or a few case reports [well-designed
randomized controlled trials or well-designed nonrandomized studies (e.g., cohort studies,
case-control studies, observational studies)].
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Pharmacist in off-label prescribing - final
Block Filter

Q1.0
Thank you for agreeing to help a graduate student with this Master's thesis project.
Please complete this short survey as INCOMPLETE/ partial responses may NOT be analyzable.

Q1.1

Are you a pharmacist practicing in any type of hospitals?

Yes

No

If Yes Is Selected, Then Skip To End of Block

Q1.2

Researchers at the Department of Pharmacy Administration of the University of Mississippi School of Pharmacy strive to address issues
facing pharmacists, the business and profession of pharmacy, and patient care. In order to access pharmacists and pharmacy technicians for
future research, the Department intends to develop a research panel. Such panel will be used for ACADEMIC RESEARCH ONLY. It is
assured that your email id and your practice information that you provide, if any, will be under the safe custody of the Department and
managed following professional and ethical norms.

Do you wish to be considered for inclusion in the research panel being developed by the Department?

Yes

No

If No Is Selected, Then Skip To End of Survey

Display This Question:
If Researchers at the Department of Pharmacy Administration ... Yes Is Selected

Q1.3

Please provide your e-mail id(s) for participating in the research panel.
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Display This Question:
If Researchers at the Department of Pharmacy Administration ... Yes Is Selected

Q1.4

Please provide the following information.

Job title
State where you practice
Practice setting

Q1.5

If Is Displayed, Then Skip To End of Survey
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Pharmacist in off-label prescribing - final
Block 11

Q2.1

INSTRUCTIONS

Please carefully read the instructions before you answer and be assured that there are NO right or wrong answers. Without your honest and thoughtful
response, the objectives of this research will NOT be realized.

Definitions:
OFF-LABEL PRESCRIBING is the act of prescribing a medication outside its FDA-approved (labeled) recommendations, including different disease
conditions, different dosage (over or under) range, different age groups, different route of administration, and different formulations.
In this survey, we are also interested in INDICATION-BASED off-label prescribing. This occurs when a medication is prescribed outside its
FDA-recommended (labeled) disease conditions (e.g., β-blockers prescribed for the treatment of thyrotoxicosis or neurotic disorders, which are not
approved indications for β-blockers).

This survey is organized into three sections:
Section I: Questions regarding your beliefs and the roles of your physician colleagues
Section II: Clinical scenario presentation and reaction (IMPORTANT)
Section III: Demographic information

Q2.2

Section I
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Q2.3

We would like you to think about the hospital in which you practice currently. Considering the physicians who practice in your hospital,
please indicate your level of agreement or disagreement with each of the following statements using a 7-point scale where 1=strongly
disagree and 7=strongly agree.
Strongly
disagree =
1

2

3

4

5

Strongly
agree = 7

6

Unless I help physicians select medications, their
job will be more difficult.
I understand that physicians really need my help
with the selection of medications.
I realize that physicians need assistance and
cooperation from those working with them.
It is clear to me that physicians really depend on
me to help select medication.
Because I respect physicians, I do not wish to
disagree with them.
I see physicians as persons with whom I can
identify.
As part of the health care team, physicians and I
should see eye-to-eye on things.
I look up to physicians to model my work.
Physicians have better rationale for selecting
medications than I do.
I have better information required for the selection
of medications than physicians possess.
I have more control over information required for
selecting medications than physicians do.
I have more access to information required for the
selection of medications than physicians do.
Physicians have more explanations for the basis
of medication selection than I do.

Q2.4

The following statements address your interactions with your physician colleagues. Please rate your behavior using a 7-point scale where
1=never and 7=always.
Never =1

2

3

4

5

6

Always = 7

I have trouble convincing physicians to do what I want them to
do.
I can persuade physicians to my position.
I accomplish my communication goals.

Q2.5

As mention before, off-label prescribing is prescribing a medication outside its FDA-approved (labeled) recommendations. Considering your
roles in off-label prescribing, please indicate your level of agreement or disagreement with the following statements on a 7-point scale where
1=strongly disagree and 7=strongly agree.
Strongly
disagree =
1
I have to evaluate off-label prescriptions in order for my
performance to be considered satisfactory.
Evaluating off-label prescriptions is my responsibility.
I consider evaluating off-label prescriptions as my obligation or
duty.
I would blame myself if I do not evaluate off-label prescriptions
satisfactorily.
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2

3

4

5

6

Strongly
agree = 7

Q2.6

Note that INDICATION-BASED off-label prescribing is prescribing a medication outside its FDA-recommended (labeled) disease conditions.
Please respond to the following statements using a scale of 1 (strongly disagree) to 7 (strongly agree).
Strongly
disagree =
1

2

3

4

5

6

Strongly
agree = 7

Indication-based off-label prescribing is important for assuring
appropriate treatment.
Indication-based off-label prescribing is advantageous for
patients.
Indication-based off-label prescribing provides effective
therapies to patients.
Indication-based off-label prescribing ensures safety.

Q2.7

Section II

Q2.8
IMPORTANT:
Please read the hypothetical situation very carefully. Imagine yourself as a pharmacist in the following situation.

Dr. Smith is a rheumatologist and joined your hospital two years ago. Dr. Smith is a highly
recognized expert in the field of rheumatology. Dr. Smith is considered an extremely
knowledgeable physician with extensive clinical experience in rheumatology. Dr. Smith has 20
years of experience of clinical practice. Previously, Dr. Smith has successfully treated
many patients with various medications prescribed for off-label indications.
Dr. Smith has written an order for fluoxetine for the treatment of fibromyalgia for Jody Jones, 35,
who was admitted to your hospital 1 day ago for a minor injury. Fluoxetine treatment has been
ordered using 20 milligrams/day for seven days and then will be titrated until 40 milligrams/day
is reached in two weeks in an out-patient setting.
Existing peer-reviewed reports on efficacy of fluoxetine in fibromyalgia are favorable. This
information is based on data derived from well-designed randomized controlled trials or
well-designed nonrandomized studies (e.g., cohort studies, case-control studies, observational
studies).

Q2.9

On the basis of the situation that was just described, please indicate your willingness to act in each of the following ways using a 7-point scale
where 1=not at all willing and 7=absolutely willing.
I am willing to ...
Not at all
willing = 1
use logic to convince Dr. Smith about the use of the medication
explain the reasons for my request as to why the medication is
appropriate or inappropriate
present Dr. Smith with the information in support of my point of
view about the use of the medication
present a detailed plan that justifies my idea about the use of
the medication
ensure rationale of this medication order with Dr. Smith
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2

3

4

5

6

Absolutely
willing = 7

Q2.10

Please indicate your likelihood of acting as described by the following statements where 1=not at all likely and 7=very likely.
Not at all
likely = 1

2

3

4

5

Very likely
=7

6

I will intervene with Dr. Smith on the medication order.
I will work with Dr. Smith on the medication order.
I will contact Dr. Smith about the medication order.

Q2.11

On the basis of the situation that was described, please indicate how acting on the prescription order may affect your relationship with the
prescriber. Please indicate your response on a 7-point scale where 1=not at all and 7=absolutely.
Contacting Dr. Smith about this
off-label prescription will ...
Not at all =
1

2

3

4

5

Absolutely
=7

6

diminish Dr. Smith’s willingness to work closely with me
diminish the likelihood that Dr. Smith will continue with my
service
diminish Dr. Smith’s trust in me
diminish Dr. Smith’s counting on my service
diminish the likelihood that Dr. Smith will seek my advice
diminish the extent of patient information sharing between
us
reduce communication between us
make Dr. Smith angry with me
make Dr. Smith annoyed
make Dr. Smith content with my service
make Dr. Smith happy with my service

Q2.12

On the basis of the information in the scenario, please indicate your level of agreement or disagreement with each of the following
statements using a 7-point scale where 1=strongly disagree and 7=strongly agree.
Strongly
disagree
=1

2

3

4

5

6

Strongly
agree = 7

Dr. Smith knows a better way of selecting a drug therapy
than I do.
Dr. Smith knows more about selecting a medication than I do.
Dr. Smith has more clinical knowledge about medicine than I
do.
Dr. Smith has more clinical knowledge about the treatment
than I do.

Q2.13

Based on the information in the scenario, please evaluate the level of appropriateness or inappropriateness of the medication order using a
7-point scale where 1=not at all appropriate and 7=very appropriate.
Not at all
appropriate
=1
In my opinion, the medication order is
Overall, the fluoxetine order for fibromyalgia is

149

2

3

4

5

6

Very
appropriate
=7

Q2.14

Section III
This section asks about you and your practice setting.

Q2.15

Gender:

Male

Q2.16

Female

What was your age on your last birthday?
Years
Age

Q2.17

Which of the following describes your pharmacy education? (check all that apply)

B.S. (Pharmacy)

Q2.18

Pharm.D.

Do you currently have any BPS specialization?

Yes

No

Display This Question:
If Do you currently have any BPS specialization? Yes Is Selected
Q2.19

IF YES: Which of the following do you hold? (check all that apply)

Nuclear Pharmacy

Q2.20

Nutrition Support Pharmacy

Oncology Pharmacy

Pharmacotherapy

Psychiatric Pharmacy

For how long have you been practicing ?
Years
In a hospital setting
In this hospital

Q2.21

What percentage of your working hours, on average, do you spend in each of the following activities? (Please be sure the rows sum to 100%)
%
Distributive pharmacy services
Direct patient care/clinical pharmacy services
Administrative duties
Other
Total

Q2.22

What title best describes your job? (check all that apply)

Clinical pharmacist

Staff pharmacist

Pharmacy manager

Other (specify)
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Consultant pharmacist

Pharmacy Director

Q2.23

Is your hospital an academic medical center?

Yes

Q2.24

Q2.25

Q2.26

The ownership status of your hospital is . . . (check only one)

a private community hospital (not-for-profit)

a federal hospital

a private community hospital (for-profit)

a university hospital

a public community hospital

other (specify)

In what state is your hospital located?

Does your hospital have an Institutional Review Board (IRB)?

Yes

Q2.27

No

No

Does your hospital have any policy regarding off-label prescribing?

Yes

No

Display This Question:
If Does your hospital have any policy regarding off-label pr... Yes Is Selected
Q2.28

Q2.29

Q2.30

IF YES, please describe briefly this policy.

Please describe if you have any thing to share about this study or your experience about off-label prescribing.

Do you wish to receive a summary report of this study?

Yes

No

Display This Question:
If Do you wish to receive a summary report of this study? Yes Is Selected
Q2.31

Please provide your e-mail id(s).

E-mail id(s)
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Q2.32

Researchers at the Department of Pharmacy Administration of the University of Mississippi School of Pharmacy strive to address issues
facing pharmacists, the business and profession of pharmacy, and patient care. In order to access pharmacists and pharmacy technicians for
future research, the Department intends to develop a research panel. Such panel will be used for ACADEMIC RESEARCH ONLY. It is
assured that your email id will be under the safe custody of the Department and managed following professional and ethical norms.

Do you wish to be considered for inclusion in the research panel being developed by the Department?

Yes

No

If No Is Selected, Then Skip To End of Survey

Display This Question:
If Researchers at the Department of Pharmacy Administration ... Yes Is Selected
Q2.33

Please provide e-mail id(s) for participating in the research panel. In case you wish to be contacted at the address, which you have already
specified, if any, skip this question.

Q2.34

If Is Displayed, Then Skip To End of Survey
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Email Cover Letter 1
Dear Pharmacist,
Subject: Please participate in a Master's thesis project on off-label prescribing
This is to request your participation in a University of Mississippi-led research project on offlabel prescribing that is largely prevalent in US hospitals. Currently, there is a lack of knowledge
on pharmacists' beliefs and opinions about off-label prescribing. Such information is believed to
provide insight on the off-label prescribing practice and may be utilized for the advancement of
pharmacy practice.
Please complete this short survey (approximately 15 minutes) in a single attempt as partially
completed responses can NOT be saved for a later attempt and avoid incomplete responses.
Please be assured that your responses will be kept confidential and anonymous. As an
appreciation of your time and effort, we offer you a summary report of this study. If you wish to
participate, please click on the link below.
http://survey.qualtrics.com/SE?SID=SV_9XLL9OWrNqPKxsE
This study has been approved by the Institutional Review Board (IRB) at the University of
Mississippi. Should you have any questions or concerns, please contact the University's IRB at
662-915-7482. Thank you in advance for your time and support.
Sincerely,
Ram Sankar Basak, B.Pharm.
Graduate Student, University of Mississippi School of Pharmacy
Faser 211, University, MS 38677
Phone: 662 801 6484 (M)
Fax: 662 915 5102
Email: rsbasak@olemiss.edu
David J. McCaffrey, R.Ph., Ph.D.
Professor
University of Mississippi School of Pharmacy
Faser 217A, University, MS 38677
Phone: 662 915 5490 (O)
Email: davidjm@olemiss.edu
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Email Cover Letter 2 (Reminder)
Dear Pharmacist,
Subject: Please participate or complete your participation in an academic off-label prescribing
study
This is a friendly reminder about your participation in an off-label prescribing survey. If you
have already done so, please accept our thanks and disregard this email.
As a pharmacist, your beliefs and opinions about off-label prescribing will provide insight on the
off-label prescribing practice and may be utilized for the advancement of pharmacy practice.
This survey will take approximately 15 minutes to complete. Please complete it in a single
attempt because partially completed responses can NOT be retrieved after you close the browser.
If you have not completed the survey previously, please do now as partly completed responses
may NOT be analyzable. Please be assured that your responses will be kept confidential and
anonymous. As an appreciation of your time and effort, we offer you a summary report of this
study. If you wish to participate, please click on the link below.
http://survey.qualtrics.com/SE?SID=SV_9XLL9OWrNqPKxsE
This study has been approved by the Institutional Review Board (IRB) at the University of
Mississippi. Should you have any questions or concerns, please contact the University’s IRB at
662-915-7482.
Thank you in advance for your time and support.
Sincerely,
Ram Sankar Basak, B.Pharm.
Graduate student
University of Mississippi School of Pharmacy
Faser 211, University, MS 38677
Fax: 662 915 5102
Email: rsbasak@olemiss.edu
David J. McCaffrey, R.Ph., Ph.D.
Professor
University of Mississippi School of Pharmacy
Faser 217A, University, MS 38677
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Dear Dr White,
Subject: Request for access to members for an academic research
Off-label prescribing – especially, for medications prescribed for uses other than their approved
ones – has garnered the attention of many stakeholders in healthcare, including physicians,
lawmakers, and payers. Although off-label prescribing is believed to be driven by unmet
pharmacotherapeutic needs it, if not practiced judiciously, has the potential of causing
detrimental effects because of reasons including but not limited to the fact that safety and
efficacy/effectiveness of such use may not be well assessed. Unfortunately, pharmacists’ beliefs
and attitudes toward this behavior as well as their perceptions of their roles and responsibilities
in the off-label prescribing process remain largely unexplored. Researchers at the University of
Mississippi School of Pharmacy believe that a study on the pharmacists’ role in off-label
prescribing will generate knowledge that has the potential to improve patient care and advance
pharmacy practice.
Because of budgetary constraints and the demands of the research design employed, we have
determined that an Internet-based survey would be the most appropriate method of data
collection. However, we do not have e-mail access to pharmacists who are practicing in
community hospitals. As a responsible and caring organization of health-system pharmacists,
your support of this study will be greatly appreciated. In other words, we would appreciate your
organization’s support for this research by sharing our offer to participate with your members.
We do not require that you send your membership list to us. However, we require only that you
forward our request to your pharmacist colleagues.
Please note that this study will not be fielded until it has met all of the human subject protections
required by our Institutional Review Board (IRB) and federal law. We assure you that we will
maintain professional norms and we will protect the confidentiality and anonymity of your
members who choose to participate in the study. As an appreciation of your participation and
support, we will submit a summary report of the findings of the study to your organization.
We believe that the results from this Master’s thesis project will have implications for
pharmacists and facilitate pharmacists' professional advancement. We will gladly provide
further information, if needed. Please let us know at your earliest convenience if you agree to
participate.
Thank you in anticipation of your support.
Sincerely,
Ram Sankar Basak, B.Pharm.
Graduate student
The University of Mississippi School of Pharmacy
662 801 6484 (M)
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Email: rsbasak@olemiss.edu
David J. McCaffrey III, Ph.D.
Thesis Advisor
Associate Professor
The University of Mississippi School of Pharmacy
662 915 5490 (O), 662 915 5102 (F)
Email: davidjm@olemiss.edu
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